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ABSTRACT OF THE DISSERTATION
Regulation of host-microbe interactions in autoimmunity and antiviral immunity by cytosolic
nucleic acid sensing and interferon signaling
by
Derek J. Platt
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2021
Professor Jonathan J. Miner, Chair
Cytosolic nucleic acid sensing and interferon (IFN) signaling are central to the host
immune response to microbial pathogens. However, dysregulation of immunological pathways
such as these can result in devastating autoimmune disease. In order to provide a robust immune
response to pathogen without causing harm to self, the host immune system must engage in a
delicate balancing act, interacting with microbes and determining whether they are commensal or
pathogenic. The cGAS-STING pathway is a key regulator of host-microbe interactions by
cytosolic nucleic sensing and IFN signaling. Loss of function in the cGAS-STING pathway leads
to increased susceptibility to pathogenic threats, including those caused by flaviviruses such as
West Nile virus. However, STING gain-of-function mutations can cause autoimmune disease in
both humans and mice. Here, we investigate the contributions of cytosolic nucleic acid sensing
and IFN signaling to the regulation of host-microbe interactions in antiviral immunity and
autoimmune disease.

xiii

Flavivirus infections represent a major global public health concern. Due to the 20152016 Zika virus (ZIKV) epidemic in Latin America, host-pathogen interactions at barrier sites
such as the placenta and cornea are a topic of heavy research interest. Furthermore, the question
of whether ZIKV is unique among flaviviruses in its ability to cross the placenta and cause
congenital infection remained. Using murine models and human explants, we discovered that
ZIKV-related flaviviruses, WNV and Powassan virus (POWV), have the capacity to infect both
the mouse and human placenta, and cause fetal demise in mice. In contrast, alphaviruses
chikungunya virus (CHIKV) and Mayaro virus (MAYV) are unable to cause fetal demise in
mice, and replicate poorly in the mouse placenta and in human placental explants. Whereas IFN
stimulated genes (ISGs) are up-regulated in the placenta and fetus of WNV- and POWV-infected
animals, CHIKV and MAYV infection did not increase ISG levels. Whether IFN signaling at the
maternal-fetus interface played a role in the pathogenesis of WNV and POWV was not
determined. However, subsequent studies demonstrated that type I IFN signaling is detrimental
to the mouse fetus during congenital ZIKV infection. Thus, the possibility that IFN signaling
contributes to viral pathogenesis in our congenital infection model remains unknown. We
additionally investigated IFN signaling at another barrier surface, the cornea. Whereas type I and
type II IFN signaling during corneal infection is well-studied, less is known about type III IFN
(IFN-l) signaling during corneal infection. Using ZIKV, herpes simplex virus-1 (HSV-1), and
the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), our study
demonstrated that IFN-l signaling can be activated in the cornea to restrict viral replication.
Moreover, IFN-l induces ISG expression in the cornea in a manner dependent on the IFN-l
receptor (IFNlR1), and blockade of IFNlR1 renders the cornea more susceptible to infections
by ZIKV and HSV-1, but not SARS-CoV-2.
xiv

Type I, II, and III IFN production can be induced by signaling through the cGAS-STING
pathway. Gain-of-function mutations in STING, which result in constitutive up-regulation of
IFNs, can cause STING-associated vasculopathy with onset in infancy (SAVI), a rare
interferonopathy characterized by pulmonary fibrosis, skin lesions, recurrent infections, and T
and NK cell cytopenia. Although STING is a sensor of host- and bacteria-derived cyclic
dinucleotides (CDNs), prior studies had not investigated the role of bacteria and bacterial
products in the development of STING-associated vasculopathy. We discovered that STING is
hyper-responsive to bacterial CDNs. Furthermore, depletion of gut microbes with an oral
antibiotic cocktail (vancomycin, neomycin, ampicillin; VNA) leads to near eradication of
perivascular inflammation in the lung. However, addition of metronidazole eliminates the
protective effects of VNA antibiotics. Surprisingly, germ-free SAVI mice still develop
autoinflammatory lung disease, but lung disease can be rescued by recolonization with
Bacteroides thetaiotaomicron or Bacteroidales-enriched stool from VNA-antibiotics treated
mice. Furthermore, treatment with short-chain fatty acids, common biproducts of Bacteroidales
bacteria, also prevents the development of lung disease. Although we did not determine the
precise immunological mechanism of protection, we demonstrated that a metronidazole-sensitive
anaerobe of the order Bacteroidales has the capacity to protect against autoinflammatory lung
disease in SAVI mice.
Collectively, these studies have helped to improve our understanding of the ways in
which cytosolic nucleic acid sensing and IFN signaling regulate host-microbe interactions within
the context of antiviral immunity and autoimmune disease. Our virus studies have provided key
insights into viral pathogenesis and IFN signaling at the maternal-fetal interface and the cornea.
Furthermore, our discovery that microbial composition can regulate the development of
xv

interferonopathy in SAVI mice may pave the way for more host-microbe studies and lead to
novel

therapeutics

for

monogenic

autoimmune

xvi

diseases

such

as

SAVI.

Chapter 1
Introduction and Background

1

Pattern Recognition Receptors
Infection by pathogenic microorganisms represents a prevalent risk to human health. Thus,
humans have evolved numerous mechanisms to combat pathogenic threats from viruses,
bacteria, and eukaryotic microbes. One such protective mechanism is the existence of pattern
recognition receptors (PRRs)1,2. PRRs, which may be localized at the plasma membrane3,4, in the
cytosol5,6, or in endosomes7,8, play a key role in the host immune response to pathogens by
recognizing a broad array of microbial antigens known as pathogen-associated molecular
patterns (PAMPs)9. These PAMPs include molecules such as lipopolysaccharide (LPS),
lipoproteins, flagellin, DNA, and RNA. There are several known subcategories of PRRs,
including the following: Toll-like receptors (TLRs)10,11, C-type lectin receptors (CLRs)12,
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs)13, retinoic acidinducible gene-I (RIG-I)-like receptors (RLRs)14, and absent in melanoma 2 (AIM2)-like
receptors (ALRs)15. Upon binding to their cognate ligand, PRRs initiate signaling cascades that
activate both innate and adaptive immune responses, leading to the up-regulation of numerous
host immune pathways such as the type I interferon (IFN) response.
Type I IFN signaling is a crucial component of the innate immune system, especially in
the context of viral infections. It is mediated by type I IFNs, a family of antiviral cytokines that
includes IFN-a, IFN-b, IFN-w, IFN-e, and IFN-k, with genes clustered on chromosome 9 in
humans (chromosome 4 in mice)16. Of these IFNs, the most well studied are IFN-a and IFN-b.
IFN-a genes are composed of 13 subfamily genes in humans (14 in mice), whereas only one
IFN-b gene is known16. All type I IFNs bind to the type I IFN a/b receptor (IFNAR), which is
composed of two subunits, IFNAR1 and IFNAR2, and is expressed on most cell types17. During
viral infection, PRRs recognize PAMPs and subsequently activate signaling pathways that
2

induce antiviral and inflammatory responses18. Once activated, PRR pathways facilitate the
phosphorylation and activation of IRF3 and/or IRF7, inducing the expression and secretion of
type I IFNs. Type I IFNs then bind to IFNAR and activate Janus kinase 1 (JAK1) and tyrosine
kinase 2 (TYK2), which phosphorylate signal transducers and activators of transcription 1
(STAT1) and STAT219. STAT1 and STAT2 then dimerize and translocate to the nucleus, where
they complex with IRF9 to form IFN stimulated gene factor 3 (ISGF3). After assembly, ISGF3
binds to IFN stimulated response elements (ISREs), which induces the transcription of hundreds
of IFN stimulated genes (ISGs), putting the cell in an antiviral state.

Zika Virus Immune Antagonism and Immunopathology
Host immune signaling pathways are crucial to the restriction of several viruses,
including those within the Flaviviridae family. The Flaviviridae family is comprised of a diverse
group of RNA viruses, including more than 70 flaviviruses that are transmitted by mosquitos
(e.g., Zika (ZIKV), Dengue (DENV), West Nile (WNV), St. Louis encephalitis (SLEV), Yellow
Fever (YFV), Japanese encephalitis (JEV) viruses) and ticks (e.g., Powassan (POWV) and Tickborne encephalitis (TBEV) viruses).
In order for ZIKV and related flaviviruses to replicate efficiently in humans, they must
antagonize the type I IFN response and/or activation of PRRs. Immune antagonism is achieved
mainly through non-structural proteins. One study demonstrated that in transfected HEK-293T
cells, ZIKV NS1 inhibits IFN-b production in a RIG-I expression-induced activation assay20.
Interestingly, two separate ZIKV strains exhibited different levels of IFN-b production
antagonism, with the African strain (FSS13025) reducing IFN-b expression by 30% and the
Asian strain (PRVABC-59) reducing IFN-beta expression by 40%. The Asian strain was found
3

to have a single amino acid change (A188V) that allows the virus to bind to and inhibit the
phosphorylation of TBK1. This study utilized the same system in conjunction with expression of
components from the RIG-I signaling pathway and ZIKV NS proteins, and found that expression
of ZIKV NS2A, NS2B, NS4A, and NS5 also suppresses IFN-b production, with activity not
varying significantly between the African and Asian lineages20. A common mechanism by which
several flaviviruses inhibit the type I IFN response is through antagonism of JAK/STAT
signaling. ZIKV prevents type I IFN-mediated phosphorylation of STAT1 and STAT2 in human
DCs21. Similar to DENV, ZIKV antagonizes human STAT2 by targeting the protein for
proteasomal degradation by NS5. Although unlike DENV, ZIKV NS5 does not utilize the E3
ubiquitin ligase, UBR4. Due to successful host immune antagonism and replication in humans,
many flaviviruses are neurotropic and have the capacity to invade the brain and cause
encephalitis (e.g., WNV, ZIKV, SLEV, JEV, YFV, POWV, TBEV). By contrast, DENV is less
neuroinvasive, but causes large epidemics of fever in humans, including life-threatening
hemorrhagic fever, with nearly 400 million infections per year22. Thus, flavivirus infections
represent a major global public health concern that is being addressed with even greater urgency
since the discovery that ZIKV causes congenital infection resulting in microcephaly, blindness,
intrauterine growth restriction (IUGR), and fetal demise23-25.
Long before the discovery that ZIKV causes congenital abnormalities, there were
numerous case reports and animal studies describing transplacental infection by other
flaviviruses26-40. However, the clinical relevance of congenital flavivirus infection was not well
defined, perhaps due to the fact that some flaviviruses cause relatively smaller or geographically
confined outbreaks41. The enormity of the ZIKV epidemic in the Americas likely made the
phenomenon of congenital flavivirus infection more discoverable than it had been in previous
4

outbreaks42.

For example, an analysis of the French Polynesian ZIKV outbreak also

demonstrated an association with microcephaly, which was uncovered only in retrospect43,44. The
2013 French Polynesian outbreak also revealed an association between ZIKV infection and
Guillain-Barre syndrome45, a neurological autoimmune disease characterized by peripheral
demyelination resulting in ascending paralysis and respiratory failure requiring mechanical
ventilation. When ZIKV spread to the Americas in 2015, millions of individuals were infected
and an epidemiological association was made for the first time between ZIKV infection and
microcephaly46.
In early 2016, Brasil et al. monitored longitudinally a group of women with PCRconfirmed ZIKV infection during pregnancy47. Ultrasonographic examination demonstrated
congenital abnormalities in 42% of fetuses, with a wide range of clinical phenotypes including
IUGR, cerebellar atrophy, ventriculomegaly, diminished cerebral artery flow, anhydramnios,
cerebral calcifications, microcephaly, and fetal demise47. A subsequent study utilized magnetic
resonance and computed tomography imaging of congenitally infected neonates to describe a
variety of abnormalities within the developing human brain, including ventriculomegaly,
hypoplasia of the cerebellum and brainstem, defects in the corpus callosum, calcifications,
cortical malformations, and other abnormalities of the neonatal brain48. Thus, although
microcephaly has been the most publicized ZIKV-related congenital malformation, the clinical
consequences of congenital infection in humans are quite varied. Human brain organoid cultures
and other cell culture studies have shown that ZIKV preferentially infects and causes apoptosis
of neural progenitor cells49-51, although ZIKV also replicates to a lesser extent in mature
neurons49. ZIKV-induced apoptosis of progenitor cells likely contributes to development of
microcephaly and other neurodevelopmental outcomes humans52. In addition, infection of the
5

placenta itself and the resulting damage and immune response within the placenta also may
contribute to IUGR or play a role in the development of other fetal abnormalities53,54.
Surprisingly, type I IFN signaling, while typically protective against viral infection, might
contribute to viral susceptibility at the maternal-fetal interface. Indeed, by crossing Ifnar1-/- dams
with Ifnar1+/- sires and infecting pregnant dams with ZIKV, Yockey et al demonstrated that
Ifnar1+/- fetuses exhibited significantly higher viral burden and more pronounced
immunopathology than their Ifnar1-/- littermates55. Furthermore, similar results were observed
using poly(I:C), demonstrating that immunopathology can occur in the absence of viral infection.
Findings such as this demonstrate the complex roles that type I IFN signaling plays during
gestation and particularly at barriers such as the maternal-fetal interface, highlighting the
importance of continued investigation within this area of research.

Antiviral Type III IFN Signaling at Barrier Surfaces
The discovery of type III IFN (IFN-l) in 2003 opened up a new area of immunological
research56,57. The human genome contains genes that encode for four known IFN-l genes, which
include IFN-l1 (IL-29), IFN-l2 (IL-28A), IFN-l3 (IL-28B), and IFN-l4. Although initially
characterized as a pseudogene, IFN-l4 has since been confirmed to be a functional component of
IFN-l signaling58,59. Indeed, IFN-l4 induces antiviral activity against hepatitis C virus in vitro58.
However, the presence of a common single nucleotide polymorphism that causes a frameshift
has rendered IFN-l4 nonfunctional in a large portion of the global human population58,59. IFN-l
proteins signal through heterodimeric receptor IFNlR (IFNlR1/IL-28Ra and IL10Rb). Similar
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to type I IFN signaling, IFN-l signaling activates a JAK/STAT signaling cascade that induces
the production of ISGs. Thus, IFN-l contributes significantly to antiviral host immunity.
Due to the similarity between type I and type III IFN signaling pathways, some have
speculated that IFN-l signaling might have a redundant role in anti-microbial immunity.
However, deletion of IL-28Ra led to an increased viral load compared to WT mice in response
to vaginal HSV-2 infection, demonstrating that IFN-l signaling can confer protective immunity
in a non-redundant manner60. Furthermore, there are clear differences between the type I and
type III signaling pathways. For example, transcriptional analysis of intestinal epithelial cells
(IELs) revealed that IFN-l signaling in IELs preferentially up-regulated a different subset of
ISGs than type I IFN61. Most notably, whereas type I IFN signaling occurs ubiquitously, IFN-l
signaling functions most robustly at epithelial and mucosal surfaces, including barrier sites such
as the respiratory tract62,63, the placenta64-66, and the gastrointestinal tract63,67-69.
The type III IFN response to numerous viruses has become well studied at a variety of
barrier surfaces, but the contributions of the IFN-l response at the cornea, another barrier
surface, had not been well defined. Although multiple DNA and RNA viruses such as HSV-1
and ZIKV can cause infection in the cornea, and IFN-l signaling is known to play a role in
restricting HSV-1 and ZIKV infection at barrier surfaces, the capacity of IFN-l signaling to
restrict viral infections such as these in the cornea was not known. As a result, we sought to
better define the pathogenesis and immunopathology of both established and emerging viral
pathogens at the corneal surfaces, in addition to defining contributions of type III IFNs and
subsequent signaling.

7

Our work assessed host-microbe interactions within the context of the type I and type III
interferon responses. We found that neurotropic flaviviruses ZIKV, WNV, and POWV, but not
arthritogenic alphaviruses CHIKV and MAYV caused high levels of transplacental and
congenital infection, as well as fetal demise. We additionally discovered a significant increase in
ISGs in the placenta and fetal head of flavivirus- but not alphavirus-infected mice. Subsequent
studies by another laboratory revealed that type I IFN signaling can be detrimental during
congenital flaviviruses infection55. This occurrence may have contributed to the differences in
viral tropism and resulting immunopathology observed in our models. In comparison,
organotypic models of ZIKV infection at the maternal-fetal interface found that IFN-l signaling
protected against ZIKV replication65, suggesting differential roles of type I and type III IFN
signaling at the placenta. Similarly, we found that type III IFN signaling is protective against
ZIKV and HSV-1, but not SARS-CoV-2 replication in the human cornea. Indeed, blockade of
IFNlR1 rendered human corneal explants more permissive to ZIKV and HSV-1 infection.
Further studies on the protective capacity of IFN-l signaling may lead to the development of
novel therapeutics to help control viral infections in the cornea.

Role of cGAS-STING in Regulating IFN Production
Another cell-intrinsic pathway that activates the production of type IFNs and ISGs is the
cGMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway. As suggested by its
name, STING is a potent and essential stimulator of IFN genes, which are essential in the
inhibition of numerous viral and bacterial pathogens. Indeed, STING is activated in response to
cytosolic DNA or bacterial cyclic dinucleotides70,71. Following cellular recognition of foreign
cytosolic DNA (particularly viral DNA), cyclic GMP-AMP synthase (cGAS) catalyzes the
8

formation of a type of cyclic dinucleotide known as cyclic GMP-AMP, or cGAMP5.
Alternatively, cyclic dinucleotides produced by bacteria are also able to directly activate the
STING signaling cascade, independently of cGAS70. Once bound to cyclic dinucleotides, STING
forms a polymer at the endoplasmic reticulum (ER) and migrates to the Golgi apparatus via
COPII vesicular trafficking. At the Golgi apparatus, STING forms a complex with tank-binding
kinase 1 (TBK1), which phosphorylates and activates interferon regulatory factor 3 (IRF3).
Activated IRF3 translocates to the nucleus and activates the transcription of type I IFNs and IFNstimulated genes (ISGs)72. Alternatively, STING can be deactivated by retrograde transport via
COPI vesicles. The cGAS-STING signaling pathway is partially regulated by three-prime repair
exonuclease 1 (TREX1), which degrades ssDNA, dsDNA, and DNA:RNA hybrids73,74 that may
escape the nucleus due to genotoxic stress or acute DNA damage75-77 (Fig. 1).
STING was co-discovered in the laboratories of John Cambier, Glen Barber, and HongBing Shu71,78,79. The Cambier laboratory identified STING as a protein that interacts with major
histocompatibility class II (MHCII) to mediate aggregation-induced apoptosis in B cells78. At the
same time, the laboratory of Glen Barber discovered STING in a yeast-two hybrid screen71. They
found that STING is an ER-associated protein, and that overexpression of STING in 293T cells
induces activation of TBK1 and dimerization of IFN-regulatory factor 3 (IRF3) to induce
expression of IFN-b, a type I IFN71. Indeed, STING-deficient murine embryonic fibroblasts
(MEFs) expressed less IFN-b during viral infections70,71. Similarly, the laboratory of Hong-Bing
Shu found that over-expression of STING activates IRF3, leading to type I IFN production
during viral infection79. The relevance of STING in an animal model was demonstrated by
Ishikawa et al., who found that STING mediates protection against a variety of unrelated
pathogens including a DNA virus (herpes simplex virus 1; HSV-1), an RNA virus (vesicular
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stomatitis virus; VSV) and a pathogenic intracellular bacterium (Listeria monocytogenes)70. In
the case of each pathogen, STING-deficient animals exhibited reduced cytotoxic T cell
responses, suggesting that STING might regulate adaptive immunity in addition to regulating
induction of type I IFN. However, the molecular mechanism by which STING detects these
unrelated pathogens was not discovered until 2013, when Wu et al. found that transfection of
L929 cells with DNA led to the production of a non-protein, non-nucleic acid, heat-labile
compound that activates STING. Subsequent mass spectrometry experiments demonstrated
molecule to be the endogenous cyclic dinucleotide cGAMP80. The enzyme cGAS, which
produces cGAMP upon detection of cytosolic DNA, was identified by performing fractionation
of L929 cytosolic extracts and measuring the STING-activating capacity of those fractions5.
Subsequently, Ablasser et al. found that cGAS produces 2’3’-cGAMP, which is structurally
distinct from bacterial 3’3’-cGAMP81,82.
Whereas cGAS-mediated binding to DNA and subsequent production of cGAMP
provides a clear rationale for cGAS-STING activation during DNA virus infection, the
mechanism by which STING responds to RNA viruses has been more challenging to define.
RNA virus infections are associated with indirect activation of cGAS-STING signaling and
induction of type I IFN71,83. Indeed, genetic ablation of STING renders mice vulnerable to many
RNA viruses including VSV and West Nile virus (WNV)70,84,85. A role for cGAS-STING in
detecting RNA viruses may be explained by infection-associated release of mitochondrial DNA
into the cytosol, leading to activation of cGAS by endogenous DNA86.
Because STING-mediated IFN production plays a major role in antiviral immunity,
viruses antagonize the cGAS-STING pathway in order to create a permissive environment for
viral replication and spread. Indeed, RNA viruses have evolved various ways to antagonize
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cGAS and STING87,88. For example, Dengue virus (DENV) induces degradation of cGAS by
NS2B, and suppresses detection of mitochondrial DNA released during infection86. Moreover,
NS2B from other flaviviruses including WNV, Zika virus, and Japanese encephalitis virus also
can proteolytically cleave STING86,89. Inhibition of dimerization also can block STING
signaling; the influenza A virus (IAV) fusion peptide blocks dimerization of STING to prevent
up-regulation of ISGs downstream of STING. Blockade of STING signaling by IAV occurs
downstream of cGAS, since deletion of STING and not cGAS leads to diminished type I IFN
production following IAV infection, suggesting a cGAS-independent mechanism by which
STING regulate immunity against RNA virus infection90. Alternatively, this may indicate a role
for constitutive STING signaling during immunity against RNA viruses.
The cGAS-STING pathway also regulates IFN-mediated immunity against retroviruses,
which are RNA viruses that produce DNA as part of their replication cycle91. Infection by HIV
and other retroviruses including murine leukemia virus (MLV) and simian immunodeficiency
virus (SIV) induces IFN-b in infected cells92. Knockout of cGAS in L929 cells prevents IRF3
dimerization and IFN-b production following infection with HIV but not Sendai virus (an RNA
virus), confirming that cGAS mediates type I IFN induction during retrovirus infection92.
Furthermore, pretreatment of THP1 cells with inhibitors of reverse transcriptase but not integrase
prevents cGAMP generation, demonstrating that the generation of DNA from retroviral RNA is
required to produce cGAMP92. Although STING-mediated type I IFN production is important in
controlling both DNA and RNA viruses, IFN signaling can also be detrimental to the host. In
addition to exacerbating immunopathology at the maternal-fetal interface during viral infection,
as mentioned earlier55, excessive production of IFN outside of the context of infection can
contribute to autoimmune disease. Diseases associated with or caused by aberrant IFN
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production and signaling are known as interferonopathies93. The most well studied
interferonopathies, type I interferonopathies, are characterized by constitutive activation of the
type I IFN signaling pathway and are an active area of research within our laboratory93.

Role of STING signaling in interferonopathies
Gain-of-function mutations in STING cause STING-associated vasculopathy with onset
in infancy (SAVI), an interferonopathy characterized by increased production of type I IFNs and
ISGs, fever, skin lesions, digital ulcerations, and interstitial lung disease94. SAVI was first
described by Liu et al., who performed whole-exome sequencing of

children with life-

threatening systemic inflammation and vasculopathy94. The initially described mutations were all
within the dimerization domain, which is also known as the connector helix loop94. Reported
SAVI-causing mutations include those found in the connector helix loop (V147L, V147M,
N154S, V155M)94,95, in ligand binding pocket (C206Y)96, and at the polymeric interface
(R281Q, R284G, R284S)96-98. In cell culture, these mutations cause spontaneous activation of
type I IFN signaling in the absence of cGAS or 2’3’-cGAMP94,99. Potential mechanisms include
enhanced dimerization94 or polymerization100, spontaneous ER exit99, or destabilization of the
STING ligand-binding-domain101.
Some SAVI-associated mutations exhibit heterogeneity in disease phenotypes. Whereas
most patients with SAVI-associated STING mutations develop pediatric disease, one patient with
the V155M mutation developed a syndrome consistent with anti-neutrophilic cytoplasmic
autoantibody-associated vasculitis. This suggests that distinct clinical phenotypes and age of
onset can be associated with the same STING mutations that also cause SAVI in children102.
Recently, a recessive SAVI-causing variant also was described (R281W)103. Thus, the existence
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of SAVI patients with homozygous recessive mutations, as well as adult-onset autoimmunity,
helps to underscore variable clinical phenotypes associated with STING gain-of-function.
Whereas cell culture studies can provide key information into potential mechanisms that
underlie STING-associated autoinflammation, studies in animal models also give insights that
may define the immunological mechanisms of disease. SAVI mice that have the STING N153S
or V154M mutations develop systemic autoimmune disease characterized by failure to thrive, T
and NK cell cytopenia, perivascular lung inflammation, myeloid cell expansion, splenomegaly,
increased ISG and proinflammatory cytokine levels, and premature death104-107. STING V154M
mice also have B cell cytopenia and lung fibrosis105. Transgenic mice that express human STING
under control of the Vav promoter, and therefore exclusively in hematopoietic cells, develop a
distinct syndrome, which includes failure to thrive, joint inflammation, lymphopenia, and
elevated proinflammatory cytokines108. Additionally, human STING N154S mice develop more
severe peripheral vasculopathy that is dependent on the type I IFN receptor. Unlike STING
N153S and V154M mice, human STING N154S mice do not develop perivascular inflammation
of pulmonary fibrosis104,105,108. The absence of lung disease in human STING N154S mice
suggests that mutant STING expression in lung parenchymal cells may be required for lung
disease pathogenesis. Observations that SAVI patients exhibit elevated ISGs and type I IFN
levels have led to the characterization of SAVI as a type I interferonopathy109-111. However,
autoimmune lung disease in STING N153S mice develops independently of cGAS112,
IFNAR1105,106,112, IRF3104,106,112, and IRF7112. Despite the compromised T cell compartment in
SAVI mice, αβ T cells are required for severe lung disease in STING N153S animals112.
Interestingly, recent studies in our laboratory have demonstrated that autoinflammatory lung
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disease and T cell cytopenia require type II IFN signaling. Indeed, Ifngr1-/- STING N153S
animals are protected against lung disease and T cell cytopenia.
Although STING N153S mice do not develop pulmonary fibrosis like humans with
SAVI94, viral infection with gHV-68 causes pulmonary fibrosis in STING N153S, suggesting
that viruses can modulate the pulmonary disease phenotype85. Mice are housed in specificpathogen free facilities, but humans are constantly exposed to a variety of potential pathogens.
Unlike SAVI patients, which are not thought to be immunodeficient94, STING N153S mice are
profoundly immunodeficient. For example, STING N153S mice exhibit a 10-fold reduction in
virus-specific IgG levels and complete lethality following sublethal gammaherpesvirus-68
(gHV68) challenge85, likely due to pronounced lymphopenia and lack of lymph nodes in STING
N153S animals104-106,113. STING N153S animals also exhibit enhanced lethality to West Nile
virus (WNV) infection, demonstrating weakened immune responses to both a DNA (gHV68) and
RNA viruses (WNV)85. Additionally, separately derived and housed STING V154M mice
develop distinct pulmonary phenotypes, as one cohort develops partially penetrant lung disease
and the other develops pulmonary fibrosis105,106. Moreover, the lifespan of STING V154M mice
is demonstrably lengthened when given long-term antibiotics105. Therefore, an intriguing
possibility exists that the microbiota contributes to the differences in disease phenotypes
observed in separately-housed SAVI-mutant STING mice, perhaps due to altered responses to
the bacteria, bacterial products, viruses, or eukaryotic microbes.
The goal of this thesis work was to understand the ways in which cytosolic nucleic acid
sensing and interferon signaling regulate host-microbe interactions in autoimmunity and in
response to viral infection and related immunopathology. Here, we evaluate the contributions of
host-microbe interactions in the regulation of autoinflammatory disease in a mouse model of
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SAVI. Our previous studies demonstrated that mice with an autoinflammatory disease-causing
mutation in STING (SAVI mice) are highly susceptible to pathogenic challenge, but the role of
commensal microbes in the development of perivascular lung disease had not been previously
known. We found that an oral antibiotics cocktail, but not germ-free conditions, significantly
reduced lung disease in SAVI mice. Furthermore, protection against autoinflammatory lung
disease correlated with a relative enrichment of bacteria from the order Bacteroidales. To
confirm that Bacteroidales species bacteria had the capacity to modulate lung disease, we
recolonized microbe-depleted SAVI mice with B. theta and demonstrated protection against lung
disease. These findings showed that the composition of the gut microbiota regulates
autoinflammatory lung disease in a mouse model of SAVI. Further studies on the contributions
of protective gut bacteria and their mechanisms of protection may lead to the development of
therapies for the treatment of SAVI.
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Figure 1. STING-mediated activation of interferon signaling. TREX1 degrades DNA, thus
negatively regulating the cGAS-STING pathway. However, aberrant dsDNA that remains in the
cytosol activates cGAS, catalyzing the production of 2’3’-cGAMP and initiating the STING
signaling pathway. The STING signaling pathway can also be activated by bacterial cyclic
dinucleotides. In both circumstances, STING activation by cyclic dinucleotides leads to
polymerization of STING and COPII-mediated migration through the Golgi apparatus. At the
Golgi, STING forms a signaling complex with TBK1 and IRF3, with TBK1 phosphorylating
IRF3. Phosphorylated IRF3 translocates to the nucleus, activating type I IFN signaling.
Alternatively, STING in the Golgi can undergo retrograde transport back to the ER via COP1
vesicles.
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Chapter 2
Zika Virus-Related Neurotropic Flaviviruses Infect Human Placental
Explants and Cause Fetal Demise in Mice

Chapter 2 is taken directly from the first publication derived from this thesis. The
corresponding article was accepted for publication on December 12, 2017 in Science
Translational Medicine. The authors are Derek J. Platt*, Amber M. Smith*, Nitin Arora, Michael
S. Diamond, Carolyn B. Coyne, Jonathan J. Miner
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These authors contributed equally to this work.
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Abstract
Although Zika virus (ZIKV) infection in pregnant women can cause placental damage,
intrauterine growth restriction, microcephaly, and fetal demise, these disease manifestations only
became apparent in the context of a large epidemic in the Americas. We hypothesized that ZIKV
is not unique among arboviruses in its ability to cause congenital infection. To evaluate this, we
tested the capacity of four emerging arboviruses (West Nile virus, WNV; Powassan virus,
POWV; chikungunya virus, CHIKV; and Mayaro virus, MAYV) from related (flavivirus) and
unrelated (alphavirus) genera to infect the placenta and fetus in immunocompetent, wild-type
mice. Whereas all four viruses caused placental infection, only infection with the neurotropic
flaviviruses (WNV and POWV) resulted in fetal demise. WNV and POWV also replicated
efficiently in second-trimester human maternal (decidua) and fetal (chorionic villi and fetal
membrane) explants whereas CHIKV and MAYV replicated less efficiently. In mice, RNA in
situ hybridization and histopathological analysis revealed that WNV infected the placenta and
fetal central nervous system, causing injury to the developing brain. In comparison, CHIKV and
MAYV did not cause substantive placental or fetal damage despite evidence of vertical
transmission. Based on the susceptibility of human maternal and fetal tissue explants and
pathogenesis experiments in immunocompetent mice, other emerging neurotropic flaviviruses
may share with ZIKV the capacity for transplacental transmission, and subsequent infection and
injury to the developing fetus.
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Introduction
Zika virus (ZIKV) is a neurotropic flavivirus that belongs to the Flaviviridae
family of RNA viruses, which includes several mosquito- (e.g., Japanese encephalitis (JEV) and
West Nile (WNV) viruses) and tick- (e.g., Powassan (POWV, also known as Deer Tick virus)
transmitted viruses. Although ZIKV was first identified more than 70 years ago114, its ability to
cause congenital infection and fetal malformations was discovered only after the explosive 2015
epidemic in South America, where more than 1.5 million people were infected115. Some have
speculated that genetic evolution of ZIKV may have contributed to some of the new clinical
manifestations identified in the recent outbreaks116,117. Indeed, the emergence of a mutation in
the prM gene (S139N) in post-epidemic strains was associated with greater infectivity and injury
of neuroprogenitor cells118. Another view is that congenital infection by ZIKV may have
occurred historically but that the association between infection and microcephaly could be
detected only in the context of a large epidemic42.
We and others previously demonstrated that ZIKV infection can cause intrauterine
growth restriction, microcephaly, and fetal demise in mice54,119-121. Because ZIKV replicated
inefficiently in immunocompetent wild-type (WT) mice, most studies in pregnant mice have
used animals with genetic or acquired deficiencies in type I interferon (IFN) receptor
signaling54,119,121. Alternatively, injection of WT dams via intravenous or intrauterine routes with
high doses of ZIKV can bypass peripheral immunity, resulting in transplacental transmission and
fetal injury120,122. In comparison, there have been sporadic reports of congenital WNV infection
in humans123-125, and WNV is reportedly transmitted transplacentally in mice126, although fetal
demise, pathology and viral tropism have not been assessed. Moreover, WNV has not been
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compared directly to other arboviruses in human placental models or in mouse models of
congenital infection.
WNV and POWV can cause severe neuropathology and death in humans127,128. The
enzootic cycle of WNV is between Culex species of mosquitos and birds, with humans being
incidental dead-end hosts. WNV has caused annual outbreaks in the United States since 1999,
but these have been relatively small in comparison to the 2015 ZIKV epidemic. For example,
there have been only ~50,000 documented human cases of WNV in the last 17 years, with an
estimated seroprevalence of ~2 to 3 million129. POWV is an emerging tick-borne flavivirus that
is endemic to the Western Hemisphere. As with WNV, humans are a dead-end host for POWV,
which circulates in enzootic cycles between Ixodes ticks and rodents. POWV infections in
humans are relatively rare with only ~100 encephalitis cases reported in the United States since
2003130. However, there are concerns about the potential for increasing numbers of infections in
humans, given the growing numbers of deer testing positive for POWV in the United
States131,132, a phenomenon that may be due to an expanding tick population133.
Alphaviruses are divided into New World Alphaviruses, which typically cause
encephalitis (e.g., Venezuelan equine encephalitis virus) and Old World Alphaviruses (e.g.,
chikungunya (CHIKV), Ross River (RRV), and Mayaro (MAYV) viruses), which cause
inflammatory arthritis. Arthritogenic Old World alphaviruses also can cause encephalitis, but this
occurs primarily in neonates134. Between March 2005 and December 2006, a widespread
outbreak of CHIKV occurred on the La Réunion Island in the Indian Ocean, infecting over onethird of the island population, causing at least 9 confirmed cases of neonatal encephalitis134.
Although some reports suggested that perinatal transmission of CHIKV may have occurred in
the birth canal135,136, the presence of CHIKV RNA in the human placenta was confirmed in one
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case137, although the cell type(s) targeted by the virus was not evaluated. MAYV is another
emerging arthritogenic alphavirus that was first identified in forest workers in Trinidad in
1954138 but is now spreading in South and Central America139. The capacity of CHIKV and
MAYV to infect fetuses has not been studied in any experimental model to the best of our
knowledge.
Here, we tested whether WNV, POWV, CHIKV, and MAYV cause congenital infection
and placental and fetal pathology in utero in immunocompetent mice. Whereas all four viruses
caused varying degrees of placental infection and subsequent transmission to the fetus, only
WNV and POWV, the ZIKV-related neurotropic flaviviruses, resulted in significant fetal injury
and demise. Ex vivo viral replication studies in second trimester human placental explants
revealed similarly efficient replication of WNV, POWV, and ZIKV in both maternal and fetal
tissues, whereas CHIKV and MAYV replicated much less efficiently. Thus, multiple neurotropic
flaviviruses appear to have the capacity to infect human mid-gestation maternal and fetal tissues
and to cause fetal demise in mice.

Results
WNV and POWV cause transplacental infection and fetal demise in mice. We chose to
study the potential for congenital infection by two encephalitic flaviviruses (WNV and POWV)
and two alphaviruses (CHIKV and MAYV), which have emerged in the Western Hemisphere.
CHIKV and MAYV were selected because they have caused outbreaks in regions affected by
ZIKV. Furthermore, CHIKV can cause perinatal encephalitis in newborns135,136, suggesting a
possibility of fetal and/or perinatal transmission. To determine whether these arboviruses can
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cause congenital infection in mice, immunocompetent wild-type (WT) C57BL/6J dams were
inoculated subcutaneously at embryonic day 6.5 (E6.5) with WNV (102 focus-forming units,
FFU), POWV (103 FFU), CHIKV (103 FFU), or MAYV (103 FFU) and euthanized at E13.5 or
E18.5 as previously described54. Since WNV and POWV can cause morbidity and mortality in
some mice by day 10 after infection (Fig. S1A), we harvested fetuses only from healthyappearing dams and euthanized any pregnant dams exhibiting hunched posture or lethargy.
Similar to studies of congenital ZIKV infection54,140, we inoculated mice on E6.5 to allow time
for peripheral viral replication so that peak viremia would coincide with placentation. However,
to confirm that congenital infection occurs even after placentation, we also performed separate
experiments with the neurotropic flaviviruses (WNV and POWV) where we inoculated dams
subcutaneously on E9.5 (Fig. S1B-D).
On E13.5 after inoculation on E6.5, we observed viral RNA (vRNA) from all four
arboviruses in the placenta and fetal head, with the most severe infection of fetal tissues
occurring with WNV (~23 to 1,500-fold higher vRNA levels than POWV, CHIKV, and MAYV
in the placenta, P < 0.05 and ~3 to 16,000-fold higher vRNA levels than POWV, CHIKV, and
MAYV in the fetal head, P < 0.01) (Fig. 1A and B). In comparison, in pregnant dams, we
detected similar viral titers (P > 0.1) in the maternal spleen on E13.5 (Fig. 1C), suggesting that
the differences in placental and fetal infection among viruses were unlikely to be related to
differences in maternal viral burden. At E18.5, we saw fetal demise in approximately 50% of
flavivirus-infected animals (WNV and POWV), whereas no fetal lethality was observed in dams
infected with the alphaviruses (CHIKV and MAYV) (Fig. 1D). Thus, both ZIKV-related
neurotropic flaviviruses caused fetal demise, whereas the alphaviruses caused no gross fetal
pathology despite a similar magnitude of infection in the placenta, at least for CHIKV.
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Consistent with the range of vRNA levels in WNV-infected fetuses (Fig. 1B), we observed
variability in fetal size and resorption, even among fetuses from the same pregnant dam (Fig.
1E). Subcutaneous inoculation with WNV or POWV at a later gestational date (E9.5) similarly
resulted in transplacental transmission (Fig. S1). WNV and POWV infection induced IFNstimulated genes (ISGs, e.g., Ifit1, Ifit2, and Ifitm3) in fetuses and placentas to a greater extent
than CHIKV and MAYV (~10 to ~100-fold higher expression of Ifit1 and Ifit2 with WNV and
POWV than CHIKV, P < 0.01) (Fig. 1F), suggesting a more robust fetal immune response,
possibly due to the greater viral burden or differences in viral mechanisms of immune evasion.
Collectively, these results suggest that ZIKV is not unique among flaviviruses in its capacity to
be transplacentally transmitted at different gestational stages to elicit fetal demise in mice.
Treatment of ZIKV-infected pregnant dams with a neutralizing human monoclonal
antibody (mAb) protects the developing fetus from infection and demise141. To determine
whether therapeutic mAbs analogously protect against congenital WNV infection, we treated
dams at day E8.5, two days after inoculation of WNV, with a neutralizing humanized anti-WNV
mAb (E16) that binds the envelope protein142. Therapy with E16 reduced viral titers in the
placenta (~25-fold, P < 0.05) and fetal head (~1,000-fold, P < 0.001) compared to the isotype
control mAb (Fig. 1G) and prevented fetal demise (62% vs 100% survival, P < 0.0001) (Fig.
1H), demonstrating that transplacental WNV infection and fetal death can be prevented by
therapeutic mAbs.
WNV infects and damages the placenta and developing fetal brain. Histopathological
analysis revealed that WNV-infected placentas were smaller than mock-infected or CHIKVinfected placentas (Fig. 2A-D), similar to that seen during congenital ZIKV infection119.
However, we did not observe evidence of severe damage, necrosis, or loss of structural integrity,
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as the junctional and labyrinth layers remained intact in CHIKV- or WNV-infected placentas
(Fig. 2A-C). This finding contrasts with the more severe placental damage observed after
congenital ZIKV infection of Ifnar1-/- dams, which may reflect ZIKV-specific effects on the
placenta or greater infection of the immunodeficient Ifnar1-/- maternal decidua 54.
Congenital ZIKV infection causes apoptosis of neural progenitor cells within the
developing fetal brain
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. To determine whether CHIKV or WNV congenital infection caused

fetal brain injury, we performed histopathological analysis of fetuses on E18.5. Fetuses from
CHIKV-infected dams exhibited no evidence of brain damage compared to mock-infected
control animals (Fig. 3A and B). In contrast, WNV caused substantial damage to the developing
brain, resulting in hypocellularity of the cerebral cortex in mild cases and frank necrosis of the
fetal brain in severe cases (Fig. 3C and D, necrosis indicated by red arrows).
We next evaluated the tropism of WNV in the mouse placenta and fetus using RNA in
situ hybridization (ISH) on E13.5. WNV RNA staining was apparent throughout the junctional
zone and umbilical cord, with less prominence in the maternal decidua and labyrinth layer of the
placenta (Fig. 4A and B). In the fetus, we found high levels of WNV RNA staining in the
forebrain, hindbrain, and spinal cord of congenitally infected animals (Fig. 4C-F). Consistent
with a range in severity of viral burden measured by qRT-PCR (Fig. 1B), some fetuses were
more severely infected than others. In two of six fetuses, we observed WNV RNA in the heart,
liver, and gastrointestinal tract of the developing fetus (Fig. 4C and G, black arrows). In the
remaining four fetuses, which were less severely infected, WNV RNA was limited mostly to the
brain and spinal cord (Fig. 4C, middle panel).
Neurotropic flaviviruses replicate efficiently in human mid-gestation placental
explants. As congenital arbovirus infection in mice might be species-specific in nature, we
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determined whether our observations had relevance to human tissues. To address this issue, we
compared the ability of different arboviruses to replicate in maternal and fetal tissue explants
obtained between 16 and 23 weeks of gestation from healthy human donors. Maternal-derived
decidua and fetal-derived chorionic villi and fetal membrane were isolated, and infection of
arboviruses was assessed. As previously reported, ZIKV replicated in human placental villi,
decidua, and fetal membranes (Fig. 5A-C). We detected similarly efficient replication of POWV
and WNV in chorionic villi and maternal decidua (Fig. 5A-B). In contrast, CHIKV did not
replicate efficiently in villi or decidua (Fig. 5D and E), although we did observe limited
replication in fetal membranes (Fig. 5F). MAYV replicated in all regions of the placental
explants, but only in one of the three donor samples (Fig. 5D-F).
Immunofluorescence microscopy for dsRNA intermediates produced during viral
replication revealed that all the neurotropic flaviviruses including ZIKV propagated efficiently in
maternal-derived decidua and/or extravillous trophoblasts that remained associated with
anchoring villi, with little replication detected within floating chorionic villi, including the
syncytial layer (Fig. 6, left and middle panels). However, one difference between the two
neurotropic flaviviruses was observed in fetal membranes. The fetal membrane is a complex
multilayered tissue consisting of the amnion and chorion, with the inner amnion composed a
single layer of cuboidal epithelial cells that directly contacts the amniotic fluid and the outer
chorion composed of a reticular layer, basement membrane, and trophoblasts. We found that
ZIKV and WNV replicated in both the amniotic epithelium and the sub-epithelial layers of the
fetal membrane whereas POWV replicated only in the sub-epithelial layer, which would not
contact the amniotic fluid or fetal compartment directly (Fig. 6). We observed low-level
infection with CHIKV exclusively in the sub-epithelial layer, whereas MAYV replicated in both
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layers of the fetal membrane (Fig. 6, right panels). Thus, multiple neurotropic flaviviruses, but
not arthritogenic alphaviruses, can replicate efficiently in organoid explants derived from midgestation human placentas and are capable of infecting maternal decidua and fetal membranes.

Discussion
The 2015 epidemic prompted an intensive study of the biology of ZIKV and its potential
for teratogenicity. Some have speculated that ZIKV is unique among flaviviruses in its capacity
to cross the placental barrier to cause congenital malformations143. Our data showing that WNV
and POWV replicate efficiently in human placental explants and cause similar levels of placental
infection, trans-placental transmission, and fetal demise in immunocompetent mice suggests that
ZIKV may not be the only flavivirus with the ability to cause congenital disease. In contrast, the
arthritogenic alphaviruses CHIKV and MAYV did not cause fetal demise in mice and replicated
much less efficiently in the villi and decidua of human placental explants.
Although congenital infection of mice with neurotropic flaviviruses was described
decades ago, no studies have performed comparative analysis of multiple arboviruses in the same
model. Experiments in the 1970s showed that intravenous inoculation of WT mice with St. Louis
encephalitis virus (SLEV) resulted in severe neurological deficits in the surviving progeny,
including

encephalocele

formation,

hydrocephalus,

brain

necrosis,

and

memory

impairment144,145. Vertical transmission of JEV during pregnancy also has been established in
mice and in swine30,146,147. In 1980, a case series was published describing course of pregnancy
of five women infected with JEV; two of the women experienced spontaneous abortions, and
JEV was isolated from the fetal brain, liver, and placenta32. In the 1990s, administration of a
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yellow fever virus vaccine during pregnancy resulted in human fetal infections, revealing yet
another flavivirus with the capacity to cause congenital infection26,148,149. After WNV spread to
the Western Hemisphere in 1999, congenital infection of WNV was modeled in mice126 and in
mouse trophoblast stem cells150, although these studies did not assess the clinical or pathological
impact on the placenta or fetus. Our study shows that WNV exhibits a broad tissue tropism in the
fetus, and that congenital infection results in damage to the placenta and developing mouse brain,
leading to fetal demise. Our results, along with the previously published studies in mice and
humans, suggest that many flaviviruses (WNV, POWV, JEV, SLEV, YFV, and ZIKV) can cause
fetal disease, with congenital infection in humans documented for four of these viruses (WNV,
JEV, YFV, and ZIKV). It is possible that flavivirus infections induce pregnancy complications
and congenital malformation more often than currently appreciated.
Remarkably, several prior studies examined small cohorts of women infected with WNV
during pregnancy and their offspring125,151,152, including one study of 77 pregnant women125.
Among infants born to WNV-infected mothers, two had microcephaly, one had lissencephaly,
and eight exhibited abnormal postnatal growth125, suggesting a microcephaly rate of 2.6% in this
group of WNV-infected neonates. Given the small numbers, a statistically significant link
between congenital WNV infection and microcephaly was not established. It is worth noting that
the association of WNV infection with congenital malformation in this study resembles that
observed from a larger retrospective analysis of ZIKV-induced congenital diseases during the
2013 outbreak in French Polynesia where there were 95 cases of microcephaly in 10,000
pregnancies (rate of 0.95%) and the seroprevalence was 50%43,153. Thus, it is possible that the
rate of flavivirus-induced congenital malformations could be similar for WNV and ZIKV, but the
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overall impact of congenital ZIKV infection is much greater because of the comparatively low
seroprevalence rate of 1-5% for WNV154,155.
Since CHIKV RNA has been detected in the human placenta in one case137, we
speculated that arthritogenic alphaviruses (CHIKV and MAYV) also might be transmitted
vertically to cause fetal demise resembling congenital ZIKV syndrome. However, we observed
no evidence of fetal death or injury after congenital infection with CHIKV or MAYV in
immunocompetent mice. Why transplacental infection with the arthritogenic alphaviruses failed
to cause fetal death will require further study, but it is important to note that the route(s) of
transplacental transmission of known teratogenic viruses such as ZIKV remain poorly defined
(reviewed in156). These differences in the capacity to cause fetal demise may reflect the lack of
susceptibility of mouse fetal cells to infection, differences in cell tropism or expression patterns
of alphavirus receptors and attachment factors on maternal (decidua) and/or fetal cells, or the
inability of these viruses to reach the intra-amniotic compartment. Neurotropic alphaviruses
(e.g., Venezuelan equine encephalitis virus), which we did not test, could have greater potential
to cause fetal infection and death than CHIKV and MAYV. Alternatively, the immune response
may have a greater capacity to clear alphaviruses from the placenta and other fetal tissues.
Alphaviruses might be more vulnerable to maternal antibody-dependent cell-mediated
cytotoxicity by macrophages, natural killer cells, or neutrophils since their envelope proteins are
displayed on the plasma membrane157, in contrast to flaviviruses, which assemble in the
endoplasmic reticulum158. In human placental explants from the second trimester, both CHIKV
and MAYV replicated in fetal membranes but did not replicate efficiently in the maternalderived decidua or fetal-derived chorionic villi. Both alphaviruses failed to replicate in a layer of
the fetal membrane subjacent to the amniotic epithelial layer that would directly contact amniotic
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fluid. In contrast, ZIKV and WNV infected the amniotic epithelial layer of the fetal membrane
whereas POWV did not. Thus, in the context of human pregnancy, the amniotic epithelial layer
of the fetal membrane would be permissive to ZIKV or WNV infection once these viruses enter
the amniotic fluid129, thereby generating an additional reservoir of infectious particles that could
reach the fetus. These findings are consistent with the hypothesis that CHIKV causes neonatal
encephalitis in the context of perinatal transmission135,136 rather than transplacental infection.
Failure of CHIKV to replicate efficiently in human maternal and fetal tissues of the placenta may
explain why congenital CHIKV infection has not been described despite large outbreaks
affecting millions of individuals. Nevertheless, our in vitro studies of human placental explants
are limited by a small donor pool, as well as by gestational age and human genetic variability.
Thus, larger studies and experiments in pregnant non-human primates are needed to confirm the
physiological relevance of our studies.
One of the limitations of modeling congenital ZIKV syndrome is that ZIKV does not
replicate efficiently in immunocompetent mice, and thus dams with deficiencies in type I IFN
signaling are commonly used for congenital infection experiments when virus is introduced into
the skin54,119,121. In contrast, WNV and POWV readily disseminate in immunocompetent WT
mice, leading to infection of the placenta and transmission to the fetus.
Our observation that human mid-gestation maternal and fetal tissues support efficient
replication of multiple neurotropic flaviviruses suggests that congenital flavivirus infections
could occur on a sporadic, undetected basis in humans. These cases may largely go unnoticed
due to inadequate prenatal healthcare available to women in many regions of the world most
affected by flavivirus outbreaks. Our findings presented here, coupled with prior literature
associating other neurotropic flavivirus infections with congenital disease, indicate that greater
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surveillance of pregnancy complications and congenital anomalies associated with arborvirus
infections is warranted, particularly in regions of the world where these viruses are endemic.
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Figures

Fig. 1. ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb
treatment. Wild-type pregnant dams were inoculated subcutaneously on E6.5 by footpad
injection with 102 FFU of WNV or 103 FFU of POWV, CHIKV, MAYV, or PBS (mock) and
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tissues were harvested on either E13.5 or E18.5 as indicated. (A-C) qRT-PCR analysis of vRNA
burden on E13.5 in the placenta (A), fetal head (B) and maternal spleen (C). (D) Fetal survival as
assessed on E18.5. (E) Photograph of littermate mock- and WNV-infected fetuses at E18.5. (F)
IFN-stimulated gene (ISG) mRNA expression as measured by qRT-PCR from placenta and fetal
head on E13.5 after E6.5 infection with WNV, POWV, CHIKV or MAYV. (G-H) Pregnant mice
were inoculated subcutaneously with WNV (102 FFU) via footpad injection on E6.5, then treated
on E8.5 with a single intraperitoneal injection of 300 μg anti-WNV mAb (humanized E16) or
isotype control mAb (anti-CHIKV human mAb 4N12) mAb at E8.5. Fetal heads and placentas
were harvested on E13.5 for viral titer measurement by qRT-PCR (G), or on E18.5 to assess fetal
survival (H). Antibody treatment experiments are pooled from 3 independent experiments with 1
to 2 pregnant female dams per experiment. vRNA burden and ISG expression data represent the
mean +/- SEM for at least n = 6 tissues per group from 4 or 5 infected dams in at least 2
independent experiments. Each data point represents a biological replicate. In (A-C) and (F),
data were analyzed by one-way ANOVA. In (G), data were analyzed by Mann-Whitney test (*
P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001). The n for survival data is indicated
above each bar. Survival data were analyzed by Chi-squared test (**** P < 0.0001).

32

Fig. 2. Placental histology on E18.5 after infection with WNV and CHIKV. Wild-type
pregnant mice were infected with 102 FFU of WNV or 103 FFU of CHIKV or PBS (mock) via
footpad injection on E6.5, and placentas were harvested on E18.5 for histological analysis.
Hematoxylin and eosin (H & E) staining of placentas was subsequently performed on mock- (A),
CHIKV- (B), and WNV-infected fetuses (C). Top row = lower magnification views. Bottom two
rows = higher magnification views of the decidua (D, middle row) and labyrinth (L, bottom
row). SpT indicates spongiotrophoblasts within the junctional zone. (D) Placental diameter of
mock-, CHIKV-, and WNV-infected placentas. Data are representative of 2 independent
experiments with n = 3 tissue samples for histological analysis and n = 7 fetuses from 2 or 3
infected dams for placental diameter measurements. Scale bars = 200 µm in top row and 50 µm
in bottom two rows. Data in (D) were analyzed by ANOVA test (** P < 0.01; *** P < 0.001).
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Fig. 3. Fetal brain histology on E18.5 after infection with WNV and CHIKV. Wild-type
pregnant mice were infected with 102 FFU of WNV or 103 FFU of CHIKV or PBS (mock) via
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footpad injection on E6.5, and fetuses were harvested on E18.5 for histological analysis.
Hematoxylin and eosin (H & E) staining was performed on mock- (A), CHIKV- (B), and WNVinfected fetuses (C and D). Red arrows indicate necrosis of the brain in a severe case of WNV
fetal disease. Data are representative of 2 independent experiments with n = 3 fetuses each. Scale
bars = 200 µm in top rows and 100 µm in bottom rows.

35

36

Fig. 4. WNV tissue tropism in the mouse placenta and fetus. Wild-type pregnant mice were
infected with 102 FFU of WNV or PBS (mock) via footpad injection on E6.5, and fetuses were
harvested on E13.5 for analysis by RNA in situ hybridization (ISH). (A-B) Low and highmagnification images of RNA ISH staining of mock- and WNV-infected placenta on E13.5. D =
decidua, JZ = junctional zone, L = labyrinth, UC = umbilical cord. Scale bars = 1 mm in (A) and
100 µm in (B). (C-G) Low and high-magnification images of RNA ISH staining of mock- and
WNV-infected fetuses on E13.5. WNV RNA ISH staining in a severely infected fetuses (C),
right panel and D-G), including the forebrain (D), hindbrain (E), spinal cord (F), and
myocardium (G). Data are representative of 2 independent experiments with n = 3 placentas or
fetuses each. Scale bars = 1 mm in (C) and 100 µm in (D-G).

37

38

Fig. 5. Viral growth curves in human placental explants. (A-F) Human placenta villi,
decidua, and fetal membrane explants from three donors (age 21-23 weeks gestation) were
inoculated with 5 x 106 FFU of ZIKV, WNV, POWV (A-C), CHIKV, or MAYV (D-F),
incubated at 37°C for 2.5 h, washed, and then cultured in DMEM/F12. Small aliquots of cell
explant supernatants were collected at 3, 12, 24, 36, and 48 h and analyzed by focus-forming
assay. Data represent the mean +/- SEM from 3 or 4 organoid explants per experiment from 3
separate donors in each condition.
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Fig. 6. Immunofluorescence staining of virus-infected human placental explants. Confocal
micrographs of human placental tissues (chorionic villi, decidua, and fetal membrane) from four
donors (age 16-23 weeks gestation) that were infected with the indicated viruses (mock (PBS),
ZIKV, WNV, POWV, CHIKV, and MAYV) for 48 h. Immunofluorescence microscopy was
performed for vRNA (using anti-dsRNA antibody, green) and tissue counterstained for
cytokeratin-19 (a marker of epithelial-derived cells, including trophoblasts) or actin (in red, as
indicated below each panel). DAPI-stained nuclei are shown in blue. White boxes denote
zoomed regions shown at bottom right. Images are representative of 4 explants per experiment
from 4 separate donors in each condition. Scale bar = 50 µm.

41

Fig. S1. Survival of pregnant dams after infection at E6.5 and vRNA burden in pregnant
dams after inoculation on E9.5. (A) Pregnant dams were inoculated subcutaneously on E6.5 by
footpad injection with 102 FFU of WNV (n = 9) or 103 FFU of POWV (n = 12) and monitored
for survival. Survival data are pooled from at least 3 independent experiments. (B-D) Pregnant
dams were inoculated subcutaneously on E9.5 by footpad injection with 102 FFU of WNV or
103 FFU of POWV followed by qRT-PCR analysis of vRNA burden on E16.5 in the placenta
(B), fetal head (C) and maternal spleen (D). vRNA data represent the mean +/- SEM for at least n
= 12 tissues per group from 3 infected dams in 2 independent experiments. In (B-D), data were
analyzed by Mann-Whitney test (P > 0.1).
Materials and Methods
Study design. This study was initiated in order to compare the capacity of multiple
arboviruses (WNV, POWV (also known as Deer Tick virus), CHIKV, MAYV, and ZIKV) to
replicate in human placental explants and to cause transplacental infection in mice. Two of the
viruses (WNV and POWV) are flaviviruses, like ZIKV, whereas the others are alphaviruses
(CHIKV and MAYV). The flaviviruses were selected because they are clinically relevant
emerging arboviruses that are related to ZIKV, which causes congenital infection. The
arthritogenic alphaviruses were selected because they are clinically relevant, and also because
CHIKV is known to cause neonatal encephalitis. However, mechanisms of CHIKV transmission
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in the perinatal period are not well understood. Our initial observation was that WNV caused
more severe placental and fetal infection in mice than the other viruses, so we focused our
subsequent experiments (histology and RNA ISH) on a comparison between a flavivirus (WNV)
and an alphavirus (CHIKV). Based on the understanding that studies in mice may not always
resemble disease in humans, we also tested the capacity of each of these viruses to replicate in
mid-gestation human placental explants. Sample sizes and endpoints were selected on the basis
of our experience with the ZIKV congenital infection model and prior studies in human placental
explants. Investigators were blinded for measurements of placental diameter and other
histological assessments, but not when measuring vRNA burden or ISG expression. Primary data
are located in Table S1.
Viruses and cells. ZIKV (Paraiba) was isolated in Brazil in 2015 and propagated in Vero
cells (American Type Culture Collection, ATCC). WNV (3000.0259, passage 2) was isolated
from a human patient sample in New York in 2000 and propagated in C6/36 (Aedes albopictus)
cells. POWV (lineage 2, Spooner strain, passage 3) was originally isolated from adult deer ticks
and passaged in Vero cells

159

. CHIKV (OPY1 p142, passage 2) was isolated in La Reunion

Island in 2006 and propagated in Vero cells. MAYV (BeH407, passage 2) was provided by the
World Reference Center for Arboviruses and propagated in Vero cells.
Human placental explants. Human mid-gestation placental tissue (from 16, 19, 22, or
23 weeks of gestation) from elective terminations of normal pregnancies was obtained from the
University of Pittsburgh Health Sciences Tissue Bank through an honest broker system after
approval from the University of Pittsburgh Institutional Review Board and in accordance with
the University of Pittsburgh anatomical tissue procurement guidelines. Decidua, fetal membrane,
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or chorionic villi were isolated from intact placental tissue and cultured in DMEM/F12 (1:1)
supplemented with 10% FBS, penicillin/streptomycin, and amphotericin B.
Focus-forming assays. Vero cells were plated in DMEM supplemented with 10% FBS
(HyCloneTM, GE Healthcare Life Sciences) in a 96-well flat-bottomed plate at 4 x 104 cells/well
the evening before inoculation. On the day of infection, medium was removed and replaced with
serial dilutions of the virus stock, and the plate was incubated for 2 h at 37°C. Following
incubation, a methylcellulose overlay (1:1 1% (w/v) methylcellulose and 1X MEM
supplemented with 2% FBS) was added and incubated at 37°C for the following time periods
based on standard protocols for titering these viruses: ZIKV, 40 h; WNV, 18 to 22 h; POWV, 50
to 60 h; CHIKV, 18 to 22 h; MAYV, 18 to 22 h. After incubation, the cell monolayers were
fixed with 1% PFA in PBS for ≥ 1 h. After fixation, wells were emptied and washed four times
with PBS, followed by addition of a mouse anti-virus primary monoclonal antibody (200 ng/mL
of E60 for WNV

160

, ZV-13 for ZIKV and POWV

reactive anti-CHIKV mAb) for MAYV

157

161

, CHK-11 for CHIKV, CHK-48 (cross-

) in PermWash (0.1% saponin + 0.1% BSA in 1X

PBS, diluted 1:5 in ddH2O) for ≥ 2 h. Cells then were washed three times with PermWash, and
subsequently a horseradish peroxidase (HRP)-conjugated secondary antibody (500 ng/mL,
Sigma-Aldrich) in PermWash was added for ≥ 1 h, followed by three washes with PermWash.
Finally, TrueBlue (Kirkegaard and Perry Laboratories) substrate was added, and plates were
rocked gently at room temperature for 2 to 15 min or until spots were defined with minimal
background. Foci were counted manually by ELISPOT.
Viral growth curves and imaging of human placental explants. Second trimester
human placental tissues (age 16-23 weeks) were cultured in DMEM/F12 and plated on the day of
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infection. Explants were incubated with 5 x 106 focus-forming units (FFU) of WNV, ZIKV,
POWV, CHIKV, or MAYV for 2.5 h, and then medium was removed. Tissues then were washed
in 40 ml of PBS for 15 min followed by DMEM/F12. At 3, 12, 24, 36, and 48 h after infection,
an aliquot was removed and frozen at -80°C. The wells were supplemented with DMEM/F12
with 10% FBS after aliquot removal at each time point. Aliquots were titrated by focus-forming
assay. At the end of the 48-h growth curve, tissues were placed into 4% PFA for histological
analysis. For imaging studies, tissue was fixed in 4% paraformaldehyde (PFA) overnight,
permeabilized with 0.25% Triton X-100 for 30 min with gentle agitation at room temperature,
and then incubated with the following antibodies: recombinant mouse monoclonal anti-dsRNA
(provided by Abraham Brass, University of Massachusetts) as described previously
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, rabbit

anti-cytokeratin-19 (Abcam, ab52625), and/or counterstained with Alexa Fluor 633 conjugated
phalloidin (Invitrogen, A22284). Tissue was mounted in Vectashield containing DAPI (Vector
labs, H-1200) and imaging performed using a Zeiss 710 laser scanning microscope. Images were
adjusted for brightness and contrast and/or pseudocolored using Fiji (Image J) or Adobe
Photoshop CC.
Mouse experiments. C57BL/6J WT mice (stock #000664) were purchased from Jackson
Laboratories and housed in a specific pathogen-free mouse facility at the Washington University
School of Medicine in St. Louis (IACUC Protocol Number: 20160288; Assurance Number: A3381-01). Mice were set up for timed matings and at embryonic day E6.5, pregnant dams were
inoculated via footpad injection using 102 FFU (WNV) or 103 FFU (POWV, CHIKV, or MAYV)
diluted in phosphate buffered saline (PBS). In some experiments, mice were treated two days
after WNV infection (E8.5) with a single 300 µg dose of humanized E16
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142

or isotype control

mAb (anti-CHIKV, 4N12)

162

diluted in PBS through an intraperitoneal route. At E13.5 mice

were sacrificed and maternal spleens, fetal heads, and placentas were harvested. Four fetal heads
and placenta per dam were analyzed for viral burden, and the remaining fetuses and placentas
were used for histological analysis.
Measurement of vRNA burden in vivo. Maternal spleens, fetal heads, and placentas
were harvested and homogenized with zirconia beads in a MagNA Lyser instrument (Roche Life
Science) in 250 or 500 μL PBS and stored at -80°C. RNA was extracted using the RNeasy Mini
Kit (Qiagen). Viral RNA levels were measured by one-step quantitative reverse transcriptase
PCR (qRT-PCR) on an ABI 7500 Fast Instrument using standard cycling conditions. Viral
burden was expressed on a log10 scale as vRNA equivalents per gram after comparison with a
standard curve produced using serial 10-fold dilutions of WNV, POWV, CHIKV, or MAYV
RNA. The primer-probe sets for the tested viruses are as follows: WNV; Fwd, 5′TCAGCGATCTCTCCACCAAAG-3′; Rev, 5′ GGGTCAGCACGTTTGTCATTG-3′; Probe,
/56-FAM/TGC CCG ACC ATG GGA GAA GCT C/36-TAMSp/: POWV; Fwd, 5′GCAGCACCATAGGTAGAATGT-3′; Rev, 5′-CCACCCACTGAACCAAAGT-3′; Probe, /56FAM/TC TCA GTG G /Zen/T TGG AGA ACA CGC AT /3IABkFQ/: CHIKV; Fwd, 5′- TCG
ACG CGC CCT CTT TAA-3′; Rev, 5′- ATC GAA TGC ACC GCA CACT-3′; Probe, /56FAM/ACC AGC CTG /ZEN/CAC CCA TTC CTC AGA C /3IABkFQ/:
MAYV; Fwd, 5′-GTGGTCGCACAGTGAATCTTTC-3′); Rev, (5′CAAATGTCCACCAGGCGAAG-3′); Probe, /56-FAM/-5′ATGGTGGTAGGCTATCCGACAGGTC-3′-/36-TAMRA/).
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RNA in situ hybridization. After fetal heads and placentas were harvested from dams at
E13.5 or E18.5, they were sectioned and RNA ISH was performed with RNAscope® 2.5
(Advanced Cell Diagnostics) according to the manufacturer’s instructions, using virus-specific
probes for WNV as previously described 66.
Statistical Analysis. Unless otherwise specified, all data were analyzed using GraphPad
Prism software by Mann-Whitney or ANOVA as specified in the figure legends.
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Chapter 3
HSV-1 and Zika Virus but not SARS-CoV-2 Replicate in the Human Cornea and
are Restricted by Corneal Type III Interferon
Chapter 3 is taken directly from the second publication derived from this thesis. The
corresponding article was accepted for publication on October 9, 2020 in the Cell Reports. The
authors are Jonathan J. Miner*, Derek J. Platt*, Cyrus M. Ghaznavi, Pallavi Chandra, Andrea
Santeford, Amber M. Menos, Zhenyu Dong, Erin R. Wang, Wei Qian, Elysse S. Karozichian,
Jennifer A. Philips, Rajendra S. Apte
*These authors contributed equally to this work.
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Summary
Here, we report our studies of immune-mediated regulation of Zika virus (ZIKV), herpes
simplex virus-1 (HSV-1), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection in the human cornea. We find that ZIKV can be transmitted via corneal transplantation
in mice. However, in human corneal explants, we find that ZIKV does not replicate efficiently,
and that SARS-CoV-2 does not replicate at all. Additionally, we demonstrate that type III
interferon (IFN-l) and its receptor (IFNlR1) are expressed in the corneal epithelium. Treatment
of human corneal explants with IFN-l, and treatment of mice with IFN-l eye drops, up-regulates
antiviral interferon-stimulated genes. In human corneal explants, blockade of IFNlR1 enhances
replication of ZIKV and HSV-1, but not SARS-CoV-2. In addition to an antiviral role for
IFNlR1 in the cornea, our results suggest that the human cornea does not support SARS-CoV-2
infection despite expression of ACE2, a SARS-CoV-2 receptor, in the human corneal epithelium.
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Introduction
The Zika virus (ZIKV) epidemic and severe acute respiratory syndrome-coronavirus-2
(SARS-CoV-2) pandemic have led to speculation that these viruses may, in some cases, enter the
body through the eyes. Other viruses, including herpes simplex virus-1 (HSV-1), are well
known to efficiently replicate in the cornea. Indeed, corneal infection with HSV-1 is a major
cause of corneal damage and vision loss163. However, the immune mechanisms that regulate
infection of the human cornea are incompletely understood.
During viral infections, type I and type III interferons (IFNs) induce expression of IFNstimulated genes (ISGs) that restrict viral replication and spread54,164-166. Whereas the type I
interferon receptor (IFNAR1) is expressed ubiquitously, the type III IFN receptor (IFNlR1,
IL28RA) has a more restricted expression pattern, leading to antiviral effects that are especially
notable at barrier surfaces including the placenta, gut, urogenital tract, and blood-brain
barrier64,66,166,167. A role for IFNlR1 signaling in the human cornea has not previously been
described.
HSV-1 infection of the human cornea requires emergency treatment, including antiviral
and corticosteroid therapy to help prevent corneal opacification and to preserve vision163. HSV-1
keratitis alone is responsible for ~40,000 new cases of visual impairment and blindness globally
each year163. Other viruses, including flaviviruses (e.g., Zika virus; ZIKV) also trigger ocular
inflammation (e.g., conjunctivitis, uveitis) and can be detected in the vitreous humor in rare
cases165,168-170. Additionally, SARS-CoV-2 RNA has been detected in tears171-173, and it has been
widely hypothesized that the eye, including the cornea and conjunctiva, may serve as a route of
entry for SARS-CoV-2.
50

ZIKV does not replicate efficiently in immunocompetent mice21. Therefore, in our prior
studies of ZIKV pathogenesis in the eye, it was necessary to study immunodeficient Ifnar1-/animals that lack the type I IFN receptor165. We found that ZIKV invades and replicates in the
eyes of mice, and that ZIKV RNA was detectable in the cornea. However, we did not test
whether viral RNA found in the cornea was associated with infectious virus165. Subsequently,
humans with ZIKV infection were reported to have ZIKV RNA and infectious ZIKV in
conjunctival swabs174. ZIKV-induced uveitis and conjunctivitis also occur in humans168,169,
indicating that ZIKV can infect the eye and cause ocular inflammation.
Here, we report that HSV-1 and ZIKV, but not SARS-CoV-2, can replicate in human
corneal explants. We found that type III IFN (also known as IFN-l) and its receptor (IFNlR1)
are expressed and functional in the human and mouse cornea. Using a model of corneal
transplant in mice, we found that ZIKV is only rarely transmitted by corneal transplantation in
immunodeficient AG129 mice that lack the type I and type II IFN receptors. This led us to
hypothesize that type III IFN may play a role in controlling infection in the cornea. Indeed, we
found that type III IFN (IFN-l) and its receptor are expressed within and exhibit antiviral
activity in cultured human corneal explants. Furthermore, we found that antiviral ISGs are
constitutively up-regulated in the epithelium of human corneal explants, and that treatment of
mice with IFN-l eye drops causes IFNlR1-dependent up-regulation of antiviral ISGs. Blockade
of IFNlR1 in human corneal explants led to enhanced replication of ZIKV, and a ~10-fold
increase in replication of HSV-1. By contrast, blockade the IFNlR1 did not result in
permissiveness of human corneal tissue to infection with SARS-CoV-2. Thus, the type III IFN
receptor restricts HSV-1 and ZIKV infection in human corneal tissue. Furthermore, resistance of
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human corneal tissue to SARS-CoV-2 infection is likely regulated by a distinct antiviral
pathway.
Results and Discussion
ZIKV transmission by corneal transplantation in mice.
Although we previously detected ZIKV RNA in mouse corneas after subcutaneous
inoculation, we did not test whether this viral RNA represents infectious viral particles165.
AG129 mice, which lack both the type I and type II IFN receptors175, are highly susceptible to
ZIKV. Indeed, even a single infectious particle is sufficient to cause death in AG129 animals176.
To test whether infectious virus was present in mouse corneas following subcutaneous
inoculation with ZIKV, we intraperitoneally inoculated 8-week-old AG129 animals with corneal
homogenates after microdissection of eyes from Ifnar1-/- mice 7 days after subcutaneous
inoculation with a clinical ZIKV isolate from Brazil. Three of 11 AG129 mice inoculated with
corneal homogenates developed ZIKV encephalitis and succumbed to infection (Fig. 1A). Thus,
infectious ZIKV is associated with the corneas of Ifnar1-/- mice following subcutaneous footpad
inoculation.
Transmission of viruses by solid organ transplantation is a major clinical concern that
requires

careful

safeguards170,177.

Furthermore,

ZIKV

transmission

via

solid

organ

transplantation has been previously described in humans177. To test whether ZIKV transmission
might be possible after corneal transplantation in animals, we performed corneal transplantation
experiments in AG129 mice. Donor AG129 mice were subcutaneously inoculated with 1000
FFU of ZIKV and euthanized 7 days after infection, followed by tissue harvesting and
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microdissection of corneas. We confirmed the presence of 105-106 FFU equivalents of ZIKV in
the posterior eye, liver, spleen, brain, kidney, and serum of infected donor animals (Fig. 1B). The
donor corneas were washed extensively in PBS, and subsequently transplanted into naïve AG129
recipient mice. Six days after transplantation, recipient mice were euthanized and ZIKV RNA in
multiple organs was quantitated by qRT-PCR. Although viral RNA was detectable in multiple
organs at low levels in all recipient animals, severe infection of multiple organs occurred in just
1 of the 6 recipient mice (Fig. 1C). Thus, ZIKV can cause systemic infection following corneal
transplantation in mice, but this occurs infrequently. Next, to evaluate whether ZIKV remains
stable and infectious in cornea storage medium, we tested the stability of ZIKV in OptisolTM.
ZIKV (6 x 105 FFU per tube) was stored in Optisol at 4ºC for one month, followed by
quantitation of infectious virus by focus forming assay. By day 28, more than 103 FFU/mL of
infectious ZIKV was still present under these conditions (Fig. 1D), indicating that infectious
ZIKV can persist in conditions typical for storage of human donor corneas.
ZIKV infects the human corneal epithelium, but does not replicate efficiently in human
corneal explants.
To test whether ZIKV replicates in human corneal tissue, we performed viral growth
curve studies by inoculating human corneal explants with 3 x 106 FFU/ml of ZIKV, followed by
focus forming assays over the course of 72 hours (Fig. 1E and F). ZIKV replicated inefficiently
in just one of three human cornea donor samples (Fig. 1E), suggesting that the human cornea is
somewhat resistant to ZIKV infection. To define ZIKV tropism in the human cornea, we
performed RNA in situ hybridization (ISH) of ZIKV-infected corneal explants 24 hours after
infection (Fig. 1F). Histological analysis revealed that ZIKV preferentially infects a small
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number of corneal epithelial cells, without appreciably penetrating into deeper layers of the
human cornea. We hypothesized that constitutive IFN signaling may be controlling viral
infection in the human corneal explants, so we measured IFN and ISG expression in human
corneal explants cultured in the absence of virus. We observed expression of type III IFNs
(IFNL1, IFNL2) and IFIT1 (an ISG) mRNA, even in the absence of infection (Fig. 1G). Since
IFNL1 and IFNL2 expression is regulated by IRF3, we hypothesized that either cytosolic DNAor RNA-sensing pathways may up-regulate IFNL1 or IFNL2 via IRF3 downstream of TBK1
signaling induced by endogenous retroelements. To test this hypothesis, we treated corneas with
an antiretroviral drug (AZT) or TBK1 inhibitor (MRT67307), but neither of these inhibitors
impacted basal expression of IFNL1 or IFNL2 (Fig. S1), suggesting that basal expression of
IFNL1 and IFNL2 are regulated independently of TBK1-mediated phosphorylation of IRF3.
Treatment of mouse corneal explants with IFN-l up-regulates expression of ISGs.
Since IFN-l restricts infection at some barrier surfaces, we reasoned that topical
treatment with IFN-l eye drops might up-regulate ISG expression in mice specifically in the
cornea. To test this hypothesis, we administered 2 doses of 1 µg topical recombinant IFN-l eye
drops or PBS control to WT and Ifnlr1-/- mice, followed by microdissection of corneas and
quantitation of ISG expression by qRT-PCR. In WT mice, but not Ifnlr1-/- mice, treatment with
IFN-l caused up-regulation of multiple ISGs including Ifit2, Ifit3, and Isg15, but not Ifi27 (Fig.
2A-E). These results indicate that topical IFN-l induces antiviral gene expression in the mouse
cornea under physiological conditions.
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To determine whether IFN-l promotes antiviral immunity in the human cornea, we began
by performing RNA in situ hybridization (ISH) and discovered that IFNlR1 is expressed
specifically in the human corneal epithelium (Fig. 3A), which are target cells for viruses known
to cause corneal pathology including HSV-1178. Treatment of human corneal explants with 4 x
104 U/ml of IFN-l for 6 hours led to a ~2-fold increase in IFNLR1 mRNA (Fig. 3B), as well as a
~50-fold increase in expression of IFIT1, and a ~25-fold increase in IFIT2 (Fig. 3C and D).
IFI27 and IRF7 also were up-regulated by approximately ~3-5 fold after treatment with IFNl (Fig. 3E and F). Thus, IFN-l induces expression of antiviral ISGs in the human cornea.
To test whether IFN-l protects against infection with ZIKV, we pre-treated human donor
corneas for 1 hour with either anti-IFNlR1 mAb or a control mAb56, and then performed viral
growth curve analysis as described in Figure 1. In 2 of 5 samples, blockade of the IFNlR1
resulted in an approximately 100-fold greater ZIKV replication (Fig. 3G). However, in other
growth curve experiments of ZIKV in the human cornea, viral replication was not detected (data
not shown). This suggests that the role of IFNlR1 in controlling ZIKV infection is variable in
distinct donors.
Next, since HSV-1 is well established as a corneal pathogen in humans, we inoculated
human corneal explants with 106 PFU/mL of HSV-1 in the presence of the same blocking antiIFNlR1 mAb or control mAb56. This led to consistently enhanced replication of HSV-1 in all
infected human donor samples, with approximately 10-fold higher levels of infectious virus by
72 hours after infection (6.1 x 104 PFU/mL in anti-IFNlR1 treated, versus 6.3 x 103 PFU/mL in
control mAb-treated corneas; P < 0.005) (Fig. 3H). HSV-1 blocks the type I IFN response in
order to facilitate viral replication179, so we reasoned that HSV-1 may similarly antagonize type
55

III IFN production or signaling. Quantitation of IFNL1 and IFNL2 mRNA with and without
HSV-1 revealed that HSV-1 infection reduces expression of IFNL2 within the first 24 hours after
infection (Fig. 3I and J). RNA ISH demonstrated that IFNL1 was expressed primarily within the
corneal epithelial cells, similar to what was observed for the IFNLR1 (Fig. 3K). Thus, IFN-l and
its receptor are expressed in the human corneal epithelium, and signaling through IFNlR1
restricts replication of HSV-1 in human corneal explants.
It has been widely speculated that SARS-CoV-2 may infect the eye180, although it is
unusual for patients with SARS-CoV-2 to develop ocular symptoms. This idea is supported by
the fact that ACE2, a receptor for SARS-CoV-2, is highly expressed in the human corneal
epithelium181,182. Therefore, we tested whether a clinical isolate of SARS-CoV-2 from Seattle
could replicate in human corneal tissue. However, we detected no evidence of SARS-CoV-2
replication by qRT-PCR in seven independent donor samples. The same negative results were
obtained by plaque assay (data not shown). Positive controls were used in all experiments,
including conformation that HSV-1 could replicate in portions of the very same donor corneas.
Unlike what was observed with HSV-1 and ZIKV, blockade of IFNlR1 did not make the human
corneal tissue more permissive to infection with SARS-CoV-2 (Fig. 3L). Since the corneal
explants also include a small amount of conjunctival tissue, our findings suggest that the human
cornea and conjunctiva may not support infection with SARS-CoV-2, and that antiviral
immunity against SARS-CoV-2 in the cornea is mediated by a pathway other than type III IFN
receptor signaling. Nevertheless, further study of human patient and autopsy samples will be
necessary to confirm that the human cornea and conjunctiva are resistant to infection with
SARS-CoV-2.
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Studies of antiviral immunity at barrier surfaces previously demonstrated that IFN-l
regulates permeability of the blood-brain barrier166, protects the gut against enteric virus
infection167, and promotes antiviral immunity at the placental barrier66. We discovered that the
human corneal barrier also is a site of action for IFN-l and its receptor, and that IFNlR1
signaling inhibits replication of HSV-1 in human corneal explants. Additionally, we found that
IFN-l eye drops up-regulate antiviral ISGs in WT but not in Ifnlr1-/- corneas in mice, revealing a
capacity of IFN-l to exert a topical effect. Since the type III IFN antiviral pathway was not
previously described to have activity in the human eye, our discoveries may lead to further
exploration of the role of IFN-l and its receptor during ocular infection and inflammatory eye
disease pathogenesis in humans.
IFNlR1 signaling likely occurs in corneal epithelial cells. In support of this conclusion,
we detected expression of IFNLR1 and IFNL1 mRNA within the human corneal epithelium.
Corneal epithelial cells also are a primary target for HSV-1 infection of the cornea163,178, and we
found that blockade of IFNlR1 signaling led to more severe HSV-1 infection of human corneal
explants, indicating that type III IFN signaling in the cornea mediates protection against
herpesvirus infection. Since our experiments only tested the role of IFN-l during infection of
human corneas, future studies in mice may allow us to examine whether similar antiviral effects
occur in animal models. Although prior studies of the mouse cornea have not examined the
effect of IFNlR1 blockade or genetic deletion, treatment of mice with recombinant IL-28A
(IFN-l) impacted immune responses and infection in a model of stromal keratitis183, providing
further support for the idea that type III IFN is relevant in the eyes of mice. Future studies in
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mouse models using Cre-lox alleles for IFNlR1 and IFN-l2/3 will allow us to define the cell
type-specific effects of IFN-l and its receptor during corneal inflammation and infection.
We previously found that ZIKV infects the corneas of mice lacking the type I IFN
receptor (Ifnar1-/- mice)165. Although we confirmed that ZIKV can be transmitted by corneal
transplantation in immunodeficient mice, severe systemic infection only occurred in 1 of 6
animals. Furthermore, ZIKV replicated inefficiently in human corneal explants, suggesting that
the cornea is unlikely to be a major target of ZIKV infection despite what has been observed in
animal models. Nevertheless, ZIKV RNA has previously been detected in the vitreous humor of
a human donor sample170, and in human conjunctival swabs174, suggesting that ZIKV can
occasionally be harbored in or associated with human corneas. Since even one infection
occurring as a consequence of a corneal transplant could be harmful, there is a need to continue
screening donated corneas for arboviruses, especially in the context of virus outbreaks.
We discovered that HSV-1 has the capacity to antagonize production of IFN-l2 in the
human cornea, implying that immune evasion of IFN-l may contribute to HSV-1 disease
pathogenesis. Prior cell culture studies demonstrated that IFN-l inhibits HSV-1 replication in
astrocytes and neurons by stimulating the expression of endogenous type I IFN and ISGs184. Our
study confirms that IFNlR1 signaling restricts HSV-1 in human samples, and also reveals a role
for this pathway in the human eye.
In addition to expression in corneal epithelial cells, IFNlR1 is expressed on neutrophils,
which are known to infiltrate and damage the cornea during HSV-1 infection185. Remarkably, in
addition to controlling infection, IFN-l can ameliorate inflammatory responses mediated by
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neutrophils186. Thus, our work may inform further studies of disease pathogenesis in animals, as
well as therapies targeting IFNlR1. This may eventually lead to prophylactic or therapeutic
administration of IFN-l to control infection, or to dampen destructive immune responses in the
cornea.
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Figures and Legends

Figure 1. ZIKV Can Be Transmitted via Corneal Transplantation in AG129 Mice but
Infects Human Corneal Explants Inefficiently. (A) Survival of AG129 mice inoculated with
Ifnar1/ corneal homogenates 7 days after subcutaneous inoculation with ZIKV (n = 11) or
uninfected Ifnar1/ cornea control homogenates (n = 4). (B and C) ZIKV mRNA expression in
tissues was quantitated using qRT-PCR. Tissues were harvested from cornea donors (n = 2) and
5

recipient (n = 6) mice on days 6 and 7 after infection. (D) ZIKV (6 x 3 10 FFU) was stored in
cornea storage medium (Optisol) at 4º C for 28 days. Infectious virus was measured by focus
forming assay at the indicated time points. (E) Human donor corneas (n = 4 technical replicates
6

per donor from three independent donor corneas) were inoculated with 3 x 3 10 FFU/mL of
ZIKV (Brazil strain), and infectious virus was quantitated at the indicated time points by focus
61

forming assay. Data represent the mean ± SEM. (F) RNA ISH and histological analysis was
performed on uninfected (left panel) and ZIKV-infected (right panel) human corneal explants in
order to determine virus tropism. The black arrow indicates infected corneal epithelial cells. (G)
Baseline expression of IFNL1, IFNL2, and IFIT1 was measured using qRT-PCR in three human
donor corneas in independent experiments. Data represent the mean DCT ± SEM relative to
expression of GAPDH. Each cornea was sectioned to produce eight technical replicates per
experiment (n = 24) from three biological replicates in independent experiments.
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Figure 2. IFN-l Eye Drops Induce ISG Expression in WT but Not Ifnlr1-/- Corneas.
Adult WT and Ifnlr1-/- animals were treated with recombinant mouse IFN-l (1 µg) in 10 µL PBS
or PBS vehicle control. Mice were treated again 3 h later and then euthanized for corneal
microdissection 6 h after the first treatment. Corneas were homogenized in PBS, and mRNA was
isolated for gene expression analysis. ISG expression in corneas was quantitated using qRT63

PCR (n = 3–5 mice per group). Results represent the mean ± SEM of data pooled from two
independent experiments. Results were analyzed using the Mann-Whitney test. *p < 0.05.
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Figure 3. The IFN-l Receptor (IFNlR1) Regulates Antiviral ISG Expression and Restricts
HSV-1 Growth in Human Corneal Explants. (A) RNA ISH and histological analysis were
performed on human donor corneas to determine IFNLR1 mRNA expression in the corneal
epithelium. Panels shown are positive control housekeeping gene (left), negative control probe
(middle), and IFNLR1 (right). Scale bar, 10 µm. Data are representative of three independent
experiments with unique donor corneas. Black arrows indicate positive staining of cells for
IFNLR1. (B–F) Human donor corneas were treated with IFN-l or PBS vehicle control, and ISG
expression from human corneal explants was quantitated using qRT-PCR. Data represent the
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mean ± SEM of 12 samples, including 4 cornea segments per donor from 3 donor corneas.
Results were pooled from two independent experiments. (G) ZIKV replication in a representative
human donor cornea sample treated with anti-IFNlR1 or isotype control antibody. Infectious
units of ZIKV were quantitated by focus forming assay. ZIKV replicated in only 2 of 5 human
cornea samples under these conditions. Results were analyzed using two-way ANOVA. (H)
HSV-1 replication in human donor corneas treated with anti-IFNlR1 or isotype control antibody.
Infectious units of HSV-1 were quantitated at the 3 h eclipse phase and every 24 h thereafter by
plaque assay. Data represent the mean ± SEM of n = 12 replicates, including 4 technical
replicates per group from 3 corneas. Results in (H) were pooled from three independent
experiments and were analyzed using two-way ANOVA. (I and J) IFNL1 and IFNL2 mRNA
expression levels were quantitated using qRT-PCR 24 h after infection with HSV-1. Data
represent the mean ± SEM of mock- infected (n = 3) and infected (n = 3) human donor corneas
with 4 cornea segments per donor in two independent experiments. (K) RNA ISH and
histological analysis were performed on human donor corneas to determine IFNL1 mRNA
expression in the cornea. Scale bar, 10 mm. Data are representative of 10 samples from seven
independent donors. Samples from two donors repeatedly did not stain for positive control (or
target) and were excluded. Black arrows indicate positive staining of cells for IFNL1. (L) SARSCoV-2 replication in human donor corneas samples treated with anti-IFNlR1 or isotype control
antibody. SARS-CoV-2 mRNA expression was measured using qRT-PCR. Data represent the
mean ± SEM of n = 7–11 replicates, with two to four technical replicates per group from 3 donor
corneas. Results in (L) were pooled from two independent experiments and were analyzed by
two-way ANOVA. Results in (B)–(F), (I), and (J) were pooled from two independent
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experiments and were analyzed using the Mann-Whitney test. *p < 0.05, **p < 0.01, ***p <
0.001, and ****p < 0.0001. See also Figure S1.

Figure S1. Treatment with inhibitors of TBK1 or reverse transcriptase does not impact
expression of IFNL1 or IFNL2 in the human cornea. Related to Figure 3. (A-D) Human
donor corneas were treated with TBK1 inhibitor (MRT 67307), an anti-retroviral drug (AZT), or
DMSO vehicle control for 6 hours, and then IFNL1 and IFNL2 mRNA expression was
quantitated by qRTPCR. Data represent the mean +/- SEM of human donor corneas (n = 3) with
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4 cornea segments per condition pooled from 2 independent experiments. Results were analyzed
by Mann-Whitney test.
STAR Methods
RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by
the Lead Contact, Jonathan J. Miner (miner@wustl.edu).

Materials Availability
This study did not generate new unique reagents. Commercially available reagents are indicated in the
Key Resources Table.

Data Availability
This study did not generate/analyze datasets/code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines. Vero CCL81 cells were used to passage and titrate ZIKV and HSV-1. Vero E6 cells
were used to passage and titrate SARS-CoV-2. Both cell lines were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL
penicillin/streptomycin, 10mM HEPES buffer, 1mM sodium pyruvate, and 1 x non-essential
amino acids. Cell lines were kept at 37ºC in a humidified atmosphere at 5% CO2.
Viruses. ZIKV (Brazil strain) was a passage 3 stock derived from a clinical isolate from Paraiba,
Brazil. Viral titers were measured by focus forming assay as previously described54. ZIKV was
68

passaged in Vero CCL81 cells. HSV-1 strain 17+ also was passaged in Vero CCL81 cells and
provided by T. Margolis (Washington University, Saint Louis, MO). SARS-CoV-2 (2019 nCoV/USA_WA1/2020) was obtained from the Centers for Disease Control and Prevention (gift
of Natalie Thornburg) and was passaged in Vero CCL81 cells. SARS-CoV-2 titers were
measured by qRT-PCR and by infectious plaque assay in Vero E6 (CRL-1586) cells187.
Mouse experiments. All protocols for animal studies were approved by the Institutional Animal
Care and Use Committees at the Washington University School of Medicine (assurance no. A3381-01). Mice were housed in specific pathogen-free mouse facilities at the Washington
University School of Medicine. AG129 and Ifnar1-/- mice were purchased from the Jackson
laboratory.

Ifnlr1-/- mice were previously described68 and provided by M.T. Baldridge

(Washington University, Saint Louis, MO). Power analysis was conducted for Institutional
Animal Care and Use Committee-approved in vivo studies in order to determine the number of
animals needed per experimental group. At least two independent experiments were conducted to
replicate findings. No outliers were excluded from analyses. The age and number of animals
used for each experiment is listed in the figure legends.
Ifnar1-/- mice were inoculated with 103 FFU of a pathogenic clinical ZIKV isolate from
Brazil via subcutaneous footpad inoculation. Corneas were harvested 7 days post-inoculation and
homogenized. Eight-week-old AG129 mice were then inoculated intraperitoneally with corneal
homogenates in 100 µl of PBS or mock-infected cornea control samples. Mice were monitored
for 30 days to assess survival. For corneal transplantation studies, AG129 mice were inoculated
subcutaneously with 103 FFU of ZIKV. Donor mice were euthanized 7 days post-infection and
corneas were microdissected and washed repeatedly in PBS, and then transplanted to AG129
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recipients as previously described188. Recipient mice were euthanized 7 days posttransplantation, followed by dissection of tissues, homogenization, and quantitation of viral RNA
by qRT-PCR using virus-specific primers and probes as previously described54.
METHOD DETAILS
Human cornea infections and virus stability measurements. De-identified human donor
corneas were obtained from Mid-America Transplant Institute and consisted of cornea samples
found to be unsuitable for transplant. Experiments were performed on a total of 25 donor corneas
(ages of donors were 20-, 21-, 23-, 28-, 32-, 35-, 40-, 40-, 40-, 40-, 40-, 51-, 53-, 55-, 55-, 55-,
56-, 56-, 64-, 66-, 66-, 67-, 67-, 69-, and 74-years-old) from both genders. This work was IRBexempt since it involved de-identified human tissue from deceased organ donors.
For ZIKV replication studies, human corneal explants were inoculated with 3 x 106
FFU/ml of ZIKV. Corneas were washed 6 times in 50 ml of PBS, and growth curve analysis was
performed by focus forming assay as previously described54. For growth curve experiments
examining HSV-1, ZIKV, and SARS-CoV-2 replication in the presence and absence of IFNlR1
blockade, anti-IFNlR1 mAb (PBL assay science, catalog # 21885-1) and isotype control
antibody (Cat# M7894, RRID:AB_1163632), were used at a concentration of 10 µg/ml with
fresh antibody introduced every 24 hours. In 2 of 5 samples, the initial HSV-1 infection failed,
and so these samples were excluded. For SARS-CoV-2 infection studies, the inoculation dose
was 1 x 106 PFU/ml, followed by washing steps as described for HSV-1 and ZIKV. Seven
human donor samples were evaluated for SARS-CoV-2 infection, three of which were evaluated
in the presence of anti-IFNlR1 mAb or control mAb. Treatment of human corneas with
recombinant human IL-29/IFNL1 (PBL assay science, catalog #11725-1) was performed at a
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concentration of 4.35 x104 U/ml for 6 hours. Cornea storage medium (OptisolTM) was obtained
from the Washington University Department of Ophthalmology. Persistence of infectious ZIKV
in cornea storage medium was assessed by introducing 6 x 105 FFU of ZIKV into cornea storage
medium at 4ºC. Levels of infectious ZIKV were quantitated by focus forming assay every two
days for 28 days.
RNA in situ hybridization (ISH) and ISG expression. Human corneas were sectioned and RNA
ISH was performed with RNAscope® 2.5 (Advanced Cell Diagnostics) according to the
manufacturer’s instructions, using virus-specific probes for ZIKV as previously described165. To
visualize IFNLR1 and IFNL1 mRNA expression in uninfected human corneas, samples were
sectioned and RNA ISH was performed with specific probes for the IFNLR1 gene using ACD
Bio probe number 494771 RNAscope ® 2.5 (Advanced Cell Diagnostics) Probe-Hs-IFNLR1.
RNA Scope 2.5 HD red was used per manufacturer’s instructions.
Gene expression analysis and IFN-l treatment of mice. Total RNA was extracted from
microdissected corneal homogenates using the RNAeasy kit (Qiagen) according to the
manufacturer’s instructions. To test whether ISG up-regulation was dependent on IFNlR1, we
administered two doses of 1 µg of mouse IL28B/IFN-l3 in PBS (PBL assay science, catalog
#12820-1) or PBS control to WT and Ifnlr1-/- mice. Doses were 3 hours apart. Three hours after
the 2nd treatment, mice were euthanized and corneas were harvested. qRT-PCR was performed
using TaqMan RNA-to-Ct 1-Step kit (Applied Biosystems) according to the manufacturer’s
instructions. Results were calculated using the DDCt method, normalizing to GAPDH. Primers
were obtained from Integrated Device Technology (IDT).
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Human cornea inhibitor experiments. Human corneas were cut into 8 pieces per cornea and
placed individually into 24-well plates with 0.3mL media containing inhibitor or vehicle control.
Inhibitors used were 10µM MRT67307 (Selleckchem S7948) and 50µM azidothymidine (R&D
Systems 4150/50). For each donor, 4 pieces from one cornea were incubated with the inhibitor
and the remaining 4 pieces with vehicle for 6 hours at 37°C. Cornea pieces were stored at -80°C.
After thawing, pieces were transferred to gentleMACS C tubes containing 1mL DMEM + 2%
FCS + collagenase (Sigma, C0130) + dispase I (Sigma D4818) and incubated with shaking at
37°C for 2 hours. Tissues were dissociated using a gentleMACS Dissociator (Miltenyi).
Dissociated tissue was then filtered over 70µm mesh filters, centrifuged at 300 x g for 10 min at
4°C, and pellets were resuspended in 250uL RLT buffer (Qiagen). RNA was isolated using the
RNeasy mini kit (Qiagen) according to the manufacturer’s protocol. qRT-PCR was performed
using a TaqMan RNA-to-CT 1-step kit (Applied Biosystems). Results were calculated using the
threshold cycle (ΔΔCT) method, normalizing to GAPDH. Primers were obtained from Integrated
Device Technology, Inc. (IDT).
QUANTIFICATION AND STATISTICAL ANALYSIS
All data were analyzed using GraphPad Prism software by Mann-Whitney test or two-way
ANOVA, as specified in the figure legends.
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Chapter 4
Transferrable Protection by Gut Microbes Against STING-Associated Lung Disease
Chapter 4 is taken directly from the second publication derived from this thesis. The
corresponding article was accepted for publication on April 20, 2020 in Cell Reports. The
authors are Derek J. Platt, Dylan Lawrence, Rachel Rodgers, Lawrence Schriefer, Wei Qian,
Cathrine A. Miner, Amber M. Menos, Elizabeth A. Kennedy, Stefan T. Peterson, W. Alexander
Stinson, Megan T. Baldridge, and Jonathan J. Miner
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Summary
STING modulates immunity by responding to bacterial and endogenous cyclic dinucleotides
(CDNs). Humans and mice with STING gain-of-function mutations develop a syndrome known
as STING-associated vasculopathy with onset in infancy (SAVI), which is characterized by
inflammatory or fibrosing lung disease. We hypothesized that hyperresponsiveness of gain-offunction STING to bacterial CDNs might explain autoinflammatory lung disease in SAVI mice.
We report that depletion of gut microbes with oral antibiotics (VNA; vancomycin, neomycin,
ampicillin) nearly eliminates lung disease in SAVI mice, implying that gut microbes might
promote STING-associated autoinflammation. However, we show that germ-free SAVI mice still
develop severe autoinflammatory disease, and that transferring gut microbiota from antibioticstreated mice to germ-free animals eliminates lung inflammation. Depletion of anaerobes with
metronidazole abolishes the protective effect of the VNA antibiotics cocktail, and recolonization
with the metronidazole-sensitive anaerobe Bacteroides thetaiotaomicron prevents disease,
confirming a protective role of a metronidazole-sensitive microbe in a model of SAVI.
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Introduction
Stimulator of interferon genes (STING) regulates immune responses to bacteria and
viruses by responding to cyclic dinucleotides (CDNs), including the endogenous STING ligand
2’3’-cyclic GMP-AMP (cGAMP) that is produced by cyclic GMP-AMP synthase (cGAS)5.
Bacteria also produce STING-activating CDNs, including c-di-GMP, c-di-AMP, and 3’3’cGAMP82. Humans and mice with gain-of-function mutations in STING develop spontaneous
inflammation in the lungs, hypercytokinemia, and T cell cytopenia94,104. Because STING gain-offunction mutants may exhibit enhanced ligand sensitivity94, we reasoned that CDNs produced by
commensal bacteria might regulate autoimmune lung disease pathogenesis in a mouse model of
STING-associated vasculopathy with onset in infancy (SAVI).
STING responds to CDNs by activating the type I interferon (IFN) response. Bacterial
CDNs were first described nearly 30 years ago189, and can act as second messengers to regulate
bacterial processes such as biofilm formation, virulence, antibiotic production, and other
physiological processes190-192. In addition to activating the type I IFN response, CDNs are
broadly immunostimulatory molecules that regulate innate and adaptive immunity193,194. Due to
their immunostimulatory properties, CDNs have been studied extensively as adjuvants for
vaccines and were effective in preclinical studies as cancer immunotherapy195-197. However, less
is known about the role of bacterial and endogenous CDNs in autoimmune diseases, including
those caused by gain-of-function mutations in STING.
The mammalian gastrointestinal tract is colonized by trillions of commensal bacteria,
more in number and in species diversity than any other region of the body198,199. These
commensal bacteria serve multiple functions that benefit the host, including facilitation of
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nutrient metabolism and other aspects of digestion200, and development of gut-associated
lymphoid tissue201. Notably, gut bacteria and their metabolites can modulate allergic lung disease
in mice202. Unlike models of asthma or allergic airway inflammation, SAVI mice develop
inflammatory lung disease with perivascular immune cell infiltration104. Whether gut microbes
play a role in SAVI-associated lung disease was not previously studied.
Here, we report that gut anaerobes can modulate autoinflammatory lung disease in a
mouse model of SAVI. Treatment of SAVI mice with an antibiotic cocktail, which spares some
gut anaerobes, led to near-complete protection against lung disease in SAVI mice. Metagenomic
sequencing revealed species of Bacteroidales including Muribaculum and Bacteroides in animals
that were protected against systemic autoimmunity. Protection against autoimmunity was
eliminated by adding the antibiotic metronidazole, which acts on anaerobic bacteria. The
immunoprotective effects of gut anaerobes were transferrable to germ-free animals that
otherwise develop severe autoinflammatory lung disease even in germ-free conditions.
Furthermore, recolonization of microbe-depleted animals with Bacteroides thetaiotaomicron (B.
theta) prevents autoinflammatory lung disease in SAVI mice, suggesting a role for specific
commensal bacteria in regulating autoinflammatory lung disease. Our findings may lead to
further studies of microbe-host interactions in SAVI patients.
Results
Bone marrow-derived macrophages from SAVI mice are hyperresponsive to a bacterial cyclic
dinucleotide.
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We previously found that SAVI mice develop perivascular inflammation in the lung, but
not airway disease104. The perivascular lung pathology develops independently of cGAS,
suggesting that the endogenous STING ligand cGAMP is not required to initiate disease203.
Because STING also detects bacterial CDN ligands204, we hypothesized that STING N153S bone
marrow-derived macrophages (BMDMs) might exhibit enhanced responses to a bacterial CDN.
To test this hypothesis, we performed a dose-response experiment by transfecting WT and
STING N153S BMDMs with c-di-GMP. We found that transfection with c-di-GMP results in a
~2- or 3-fold higher expression of interferon-stimulated genes (ISGs) in STING N153S BMDMs
compared to WT control cells (Fig. 1A and B), suggesting that the STING mutant is
hyperresponsive to a bacterial CDN. STING signaling in antigen presenting cells can cause upregulation of MHC class II193, but the impact of STING gain-of-function on MHC class II
expression was not previously tested. In BMDMs, STING gain-of-function was associated with
higher MHC class II expression at baseline and, in response to c-di-GMP, a ~1.5-fold increase in
MHC class II up-regulation compared to WT BMDMS (Fig. 1C-E). In contrast, MHC class II
was not upregulated in response to c-di-GMP in STING GT BMDMs, which lack functional
STING signaling (Fig. 1C-E). Similarly, the costimulatory molecule CD86 was up-regulated in
both WT and STING N153S cells, but not in STING GT macrophages (Fig. 1F). In contrast,
CD80 expression was not impacted by c-di-GMP under these conditions (Fig. 1G). Collectively,
these results demonstrate that the STING N153S mutation renders BMDMs more responsive to
c-di-GMP stimulation.
Treatment with an antibiotic cocktail nearly eliminates lung disease in SAVI mice.
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Since STING N153S BMDMs are more responsive to bacterial c-di-GMP, we reasoned
that commensal bacteria may contribute to spontaneous autoimmunity and lung disease in SAVI
mice. To test our hypothesis that bacteria contribute to perivascular lung inflammation in our
model of SAVI, we administered an antibiotic cocktail of vancomycin, neomycin, and ampicillin
(VNA) to 4-week-old, co-housed WT and SAVI mice. Treatment with VNA antibiotics almost
completely eliminated histological evidence of lung disease in SAVI animals (Fig. 2A and B).
Treatment of mice for 4 weeks and subsequent removal antibiotics led to recurrence of lung
disease, suggesting a need for continuous depletion of microbes to prevent lung disease (Fig.
S1).
Since various bacteria differentially produce CDNs in response to phages205, we reasoned
that differences in microbial populations may explain the effect of antibiotics on lung disease. To
begin to characterize gut microbiota of our animals, we performed 16S and phageome analysis of
fecal samples from co-housed WT and SAVI mice. Treatment with the VNA antibiotics cocktail
almost completely depleted the gut of bacteria based on 16S analysis (Fig. 2C), although
Bacteroides species remained detectable by PCR (data not shown). In untreated, co-housed WT
and SAVI animals, mouse genotype had no effect on bacterial richness or diversity (Fig. 2D-E
and Fig. S2A). Furthermore, virome analysis revealed similar bacteriophage compositions in
cohoused WT and SAVI mice (Fig. S2B-E).
Levels of pro-inflammatory cytokines, chemokines, and ISGs are elevated in the lungs of
SAVI mice203. Treatment with VNA antibiotics caused a ~2-fold reduction in Isg15 and a ~4fold reduction in Cxcl10 expression in the lungs of SAVI mice compared to WT control animals
(P < 0.05) (Fig. 2F-L). In addition to almost completely eliminating histological evidence of
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lung disease (Fig. 2A and B), multiplex cytokine analysis of lung homogenates revealed that
pro-inflammatory cytokine and chemokine levels were returned to levels of healthy WT control
mice (Fig. 3A-C). Thus, antibiotics can eliminate autoinflammatory lung disease in SAVI mice,
but this protective effect requires continuous treatment with antibiotics.
Treatment with oral antibiotics alters immune cell populations in SAVI mice.
We previously found that ab T cells are required for severe lung disease in SAVI
mice203, so we hypothesized that treatment with the VNA antibiotics cocktail may alter immune
cell populations. Treatment of SAVI mice with oral antibiotics increased the percent of naïve T
cells while decreasing the percent and number of T effector cells (Fig. S3). However, these
relatively small alterations in T cell populations do not necessarily explain the near-complete
elimination of lung disease in SAVI animals. Since bacterial CDNs can regulate numbers of
myeloid cell populations in the peritoneum and the spleen193, we reasoned that depletion of gut
microbes may have the opposite effect on myeloid cell populations in mice. Indeed, we found
that the VNA antibiotics cocktail led to a ~4-fold decrease in the number of dendritic cells
(CD11c+ MHCII+), a ~2-fold decrease in inflammatory monocytes (CD11b+ Ly6Chi), and a ~3fold reduction in neutrophils (CD11b+ Ly6G+) in the spleens of SAVI but not WT littermate
control animals (Fig. S4). Although certain antibiotics have the capacity to alter immune cell
populations via effects on hematopoiesis206, we observed changes only in SAVI mice and not in
WT littermate control animals, suggesting a specific effect of antibiotics in STING N153S gainof-function. These results are consistent with the idea that STING N153S is hyperresponsive to
bacterial CDNs.
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Because the VNA antibiotics cocktail nearly eliminates lung disease in SAVI mice, we
hypothesized that deleterious bacteria are required to induce autoimmunity, and that
autoinflammatory lung disease would not develop in the absence of commensal microbes. To
test whether commensal microbes are required for lung disease, we generated germ-free SAVI
mice. At 4 weeks of age, we recolonized half of the germ-free SAVI animals with stool from
mice housed under enhanced specific-pathogen free (ESPF) conditions. Because antibiotics
prevent lung disease in SAVI mice, we anticipated that germ-free SAVI animals would not
develop lung disease. Unexpectedly, we found that germ-free SAVI mice still develop severe
lung disease. Indeed, the severity of disease was the same in re-colonized and germ-free SAVI
mice, demonstrating that complete elimination of commensal bacteria does not prevent lung
disease (Fig. 4A-B).
The VNA antibiotics cocktail would not be expected to eliminate all commensal
microbes, especially since these antibiotics would not fully eradicate anaerobic bacteria. For
example, we used a pan-bacteroides PCR assay to confirm that at least some Bacteroides species
likely persist after treatment with VNA (data not shown). Since germ-free SAVI mice develop
severe autoinflammatory lung disease, we reasoned that some of these gut anaerobes not
sensitive to VNA might protect against STING-associated lung disease. To determine whether
the protective factor is transferrable, we performed a fecal transplant of stool from VNA-treated
SAVI animals into germ-free SAVI mice using stool from VNA-treated SAVI animals. Two
weeks after recolonization, we histologically examined lungs and found that recolonization using
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microbes from antibiotics-treated mice resulted in prevention of autoinflammatory lung disease
in SAVI animals (Fig. 4A and B). Recolonization with stool from VNA antibiotics-treated mice
also led to a reduction in expression of Ifit1, Cxcl10, Isg15, Tnfa, but not Il10, or Tgfb1
compared to control microbiota recolonized mice (Fig. 4C-H). However, unlike antibiotics
treatment, germ-free conditions had no effect on numbers or subsets of lymphoid and myeloid
cell populations other than a small increase in CD11b+ F4/80+ myeloid cells in recolonized
animals (Fig. S5). Similarly, recolonization with VNA-treated microbes had no effect on
immune cells in SAVI animals (Fig. S6). Thus, although bacteria are not required for lung
disease pathogenesis in SAVI mice, transplant of gut microbiota from VNA antibiotics-treated
animals almost completely protects against STING-associated autoinflammatory lung disease.
Since the VNA antibiotics cocktail spares some gut anaerobes that are sensitive to
metronidazole, we hypothesized that metronidazole-sensitive microbes mediate protection
against STING-associated autoimmunity. Indeed, addition of metronidazole to the VNA cocktail
eliminated the protective effect of those antibiotics (Fig. 5). This suggests that metronidazolesensitive microbes can protect against STING-associated autoinflammatory lung disease in mice.
An isolated presence of Bacteroidales is associated with protection against STING-associated
lung disease in mice.
Because protozoa are susceptible to metronidazole, we considered that the protective,
metronidazole-sensitive microbe might be eukaryotic. However, 18S analysis of stool from
VNA-treated and untreated SAVI mice revealed no differences in the composition of the
eukaryotic gut microbiota (Fig. S7). Subsequent metagenomic analysis of stool from recolonized
and germ-free animals revealed a dramatically reduced number of bacterial reads in germ-free
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animals, as well as in germ-free mice recolonized with microbiota from mice treated with the
VNA antibiotics cocktail (Fig. 6A), while recolonization with control gut microbiota resulted in
a population of commensals similar to that of enhanced specific pathogen-free mice (Fig. 6A
and B). Shotgun metagenomic data of ESPF samples was concordant with 16S results (Fig.
S2A), reflecting classification of prior Porphyromonadaceae as Muribaculaceae in more
recently-updated databases207. In contrast, the relatively sparsely populated gut of recolonized
mice that received microbiota from antibiotics-treated mice demonstrated a predominance of
metronidazole-sensitive anaerobes of the order Bacteroidales, including gut anaerobes such as
Muribaculum (Fig. 6C-D). Collectively, these results suggest that a relative enrichment of
Bacteroidales, combined with depletion of other gut bacteria, may protect against STINGassociated autoinflammatory lung disease.
Recolonization with Bacteroides thetaiotaomicron protects against autoinflammatory lung
disease in SAVI animals.
To confirm that bacteria from the order Bacteroidales can protect against lung disease in
SAVI mice, we recolonized VNAM-treated SAVI mice with Bacteroides thetaiotaomicron (B.
theta) as a representative species for Bacteroidales and histologically assessed perivascular lung
inflammation two weeks after recolonization. We discovered that recolonization with B. theta
was sufficient to reduce lung disease in SAVI mice (Fig. 7A-B). Gene expression analysis of
select ISGs and cytokines revealed a ~2-fold reduction in Il10, as well as trends toward
diminished expression of Cxcl10 and Ifit1 (Fig. 7C-G). These data confirm the capacity of a
Bacteroides species to protect against autoinflammatory lung disease in SAVI animals.
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The short-chain fatty acids propionate and butyrate can protect against STING-associated
lung disease.
Short-chain fatty acids serve as an energy source for bacteria208, but also have the
capacity to regulate host immune responses209,210. Many bacterial species from the genus
Bacteroides produce short-chain fatty acids211, and species of genus Muribaculum also are
equipped with fermentation pathways to produce propionate212. Since recolonization with B.
theta protects against severe autoinflammatory lung disease, we hypothesized that treatment with
short-chain fatty acids would protect against lung disease in SAVI animals. We found that
treatment with propionate and butyrate led to a decrease in STING-associated autoinflammatory
lung disease, highlighting a potential role for short-chain fatty acids produced by Bacteroidales
(Fig. 7H-I). Short-chain fatty acids derived from anaerobes might be one microbial factor that
mediates protection against STING-associated autoinflammatory lung disease.
Discussion
STING gain-of-function causes severe lung disease in patients with SAVI. Because
STING responds to bacteria-derived CDN ligands, we tested whether bacteria contribute to
autoinflammatory disease pathogenesis in a mouse model of SAVI. Unexpectedly, we
discovered that STING gain-of-function causes autoinflammatory lung disease in germ-free
animals that lack commensal microbes. In addition, we discovered that modulating the
composition and abundance of commensal microbes almost completely eliminates systemic
autoimmunity in SAVI mice. Furthermore, transfer of metronidazole-sensitive Bacteroidales
bacteria to germ-free SAVI animals was associated with protection against STING-associated
lung disease.
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Liu et al. found that SAVI patient fibroblasts with STING gain-of-function mutations are
hyperreponsive to CDNs94. We previously found that STING gain-of function mice develop
autoimmunity, T-cell cytopenia, and lung disease independently of the endogenous STING
ligand cGAMP. Here, we found that STING N153S BMDMs are hyperresponsive to the
bacterial STING ligand c-di-GMP, and so we hypothesized that bacterial CDNs may be
responsible for lung disease in SAVI animals. However, our discovery that germ-free SAVI mice
still develop autoinflammatory lung disease revealed that bacterial CDNs are not required for
STING-associated autoimmunity. Nevertheless, we cannot exclude the possibility that bacterial
CDNs may influence disease severity in SAVI, perhaps in ways that were beyond our ability to
detect.
That gut microbes influence autoinflammatory lung disease confirms the presence of a
gut-lung axis in a model of SAVI. How gut microbes influence autoimmunity in the lung is less
clear. Organs previously thought to be sterile or relatively sterile have their own, distinct
microbial populations213. These distinct microbial communities do not exist in isolation and can
influence the microbiota in other organs214. Some have speculated that a gut-lung axis exists,
such that intestinal and pulmonary environments can influence each other202,215. For example,
Cooke et al. suggested a role for gut-derived lipopolysaccharide in modulating immune cell
populations and inflammatory mediators in the lung during idiopathic pneumonia syndrome after
bone marrow transplantation216. Trompette et al. found that altering the ratio of Firmicutes to
Bacteroidetes led to a reduction in Th2 responses and protection against allergic airway
inflammation202. Others have found that treatment with antibiotics that deplete gut microbes can
alter vulnerability to bacterial infections of the lung217,218. Segmented filamentous bacteria (SFB)
can induce lung inflammation in transgenic mice expressing dual SFB-specific TCRs219,
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indicating that lung inflammation can be initiated by antigen-specific T cells directed against a
gut microbe. Unlike other studies, which were primarily focused on the role of gut microbes in
regulating infection or allergic inflammation, our work reveals a role for gut microbes in
regulating autoinflammation in a lung disease caused by a human disease-associated mutation.
Furthermore, in contrast to the work of Trompette et al., our data do not suggest any alteration in
Th2 cytokines in association with the reduction in lung disease (Fig. 3). This suggests that the
mechanism of protection in our model of STING-associated autoimmunity is distinct from that
which was shown in a different model of lung disease.
We found that antibiotics caused alterations in myeloid and lymphoid cell populations,
and that those effects could not be transferred by recolonization of germ-free mice. However, we
cannot exclude the possibility that antibiotics also have microbe-independent effects on immune
cells220, which may protect against lung disease in SAVI animals. Nevertheless, transfer of
microbes into germ-free animals was protective even without appreciably altering immune cell
populations. Without our germ-free mouse studies, we might have been misled to speculate that
commensal microbes were required for STING-associated autoinflammatory lung disease. Our
results underscore the value of studies in germ-free and recolonized animals.
Anaerobes regulate immunity in other models of autoimmunity, including experimental
autoimmune encephalomyelitis (EAE). For example, Bacteroides fragilis produces molecules
including polysaccharide A, which can promote expression of anti-inflammatory cytokine IL-10
and protect against demyelination in EAE221. Lactobacillus reuteri also can suppress EAE222. In
other instances, bacterial metabolites such as short-chain fatty acids can modulate immunity and
reduce allergic inflammation in the lung202. Because STING-associated lung disease is primarily
mediated by ab T cells, one reasonable hypothesis is that a gut anaerobe metabolite mediates the
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protective effect. Indeed, we confirmed that the short-chain fatty acids propionate and butyrate,
which are common metabolites produced by anaerobes, can inhibit lung disease in SAVI
animals. However, our results also suggest that metronidazole-sensitive anaerobes protect against
STING-associated autoimmunity only upon depletion of bacteria sensitive to VNA. This implies
that protective effects of anaerobes can be inhibited by VNA-sensitive bacteria. The precise roles
and molecular mechanisms of these microbial community interactions remain to be determined.
Metagenomic analysis on animals recolonized with stool from VNA antibiotics-treated
SAVI mice revealed several anaerobic species from the order Bacteroidales, most species of
which have not been characterized. In recent years, Muribaculaceae species such as
Muribaculum intestinale were identified as a core component of the commensal microbiome of
several homeothermic species223. However, little is known about M. intestinale outside of its
existence as a commensal microorganism, and even less is known about many of the other
Bacteroidales species that are enriched in mice recolonized with stool from VNA antibioticstreated animals. Whether these bacterial populations have the capacity to modulate other
autoimmune diseases has not been investigated. Recolonization with B. theta, which we chose as
a representative species of Bacteroidales, was sufficient to diminish the severity of
autoinflammatory lung disease in SAVI animals. Although treatment with VNA antibiotics led to
the relative enrichment of several Bacteroidales-species bacteria, our finding provide evidence
that a single species can modulate perivascular inflammation in the lung, although the
immunological mechanism has not yet been elucidated.
Commensal bacteria of the order Bacteroidales can produce short-chain fatty acids211. We
found that treatment of SAVI mice with the short-chain fatty acids propionate or butyrate can
protect against STING-associated autoinflammatory lung disease, and that elimination of lung
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disease was associated with isolated colonization with Bacteroidales. Production of immunemodulating short-chain fatty acids might be one of several mechanisms by which relative
enrichment of certain bacterial species can protect against autoinflammatory lung disease in
SAVI animals. Short-chain fatty acid receptors GPR41 and GPR43 are expressed on immune
cells

224,225

and modulate inflammatory responses through inhibition of histone deacetylase

activity. Nevertheless, our studies did not definitively elucidate an immunological mechanism by
which antibiotics modulate autoinflammatory lung disease in SAVI mice. An alternative
hypothesis is that specific bacterial populations may produce small-molecule antagonists of
STING that specifically modulate inflammatory responses in our model of STING-associated
autoimmunity. Further characterization of protective gut anaerobes, including characterization of
potentially protective metabolites, may lead to novel therapies for the treatment of SAVI and
other autoimmune diseases associated with hyperactivation of the STING pathway.

Acknowledgments
We thank the Washington University School of Medicine Ophthalmology Core for histology
processing services. We thank Michael White, and Summer Rucknagel of the Washington
University in St. Louis Gnotobiotic Core for germ-free mouse generation and recolonization
services. We also thank Brock Bennion for technical assistance with tissue harvesting.
Funding: The Miner laboratory is supported by grants from the NIH (K08AR070918 and
R01AI143982). D.J.P. is supported by the Washington University Chancellors Graduate
Fellowship Program and the Initiative for Maximizing Student Development. M.T.B. is
supported by grants from the NIH (R01AI141716 and R01AI139314) and from the Children’s
Discovery Institute of Washington University and St. Louis Children’s Hospital (MI-II-201987

790). D.L. is supported by T32HG000045. Author Contributions: D.J.P., D.L, R.R., L.S.,
W.Q., C.A.M., A.M.M., E.A.K, S.T.P., and W.A.S performed experiments. D.J.P., D.L, R.R.,
W.Q., C.A.M., A.M.M., and J.J.M. analyzed data. M.T.B. and J.J.M. guided experiments. D.J.P.
wrote the initial manuscript and edited subsequent versions of the manuscript. J.J.M. edited and
wrote the final version of the manuscript. All authors reviewed and edited the final version of the
manuscript. J.J.M. conceived the project and directed all experiments. Declaration of Interests:
The authors declare no competing interests. Inclusion and Diversity Statement: We worked to
ensure sex balance in the inclusion of non-human subjects. One or more of the authors of this
paper received support from a program designed to increase minority representation in science.

88

Figures and Legends

Figure 1. STING N153S gain-of-function bone marrow-derived macrophages (BMDMs)
are hyper-responsive to cyclic di-GMP, a bacterial cyclic dinucleotide. Bone marrow-derived
macrophages (BMDMs) were isolated from WT, STING N153S (SAVI), or STING Goldenticket
mice, followed by stimulation with cyclic di-GMP or control. (A-B) Gene expression levels of
IFIT1 and ISG15 were measured in WT and STING N153S BMDMs. (C-G) Geometric mean of
(C-D) MHCII, (E) MHCI, (F) CD86, and (G) CD80 on WT, STING N153S, or STING
Goldenticket mice was measured by flow cytometry following stimulation with cyclic di-GMP
or control. Data represent the mean +/- SEM of 4 biological replicates per group, which were
pooled from 2 independent experiments. Results were analyzed by Mann-Whitney test. *, P <
0.05; **, P < 0.01.

89

90

Figure 2. Treatment with the VNA antibiotics cocktail reduces perivascular inflammation
and ISGs in the lungs of SAVI mice.

Four-week-old STING N153S (SAVI) mice were

administered vancomycin, neomycin, and ampicillin cocktail (VNA) or vehicle control ad
libitum and euthanized at age twelve weeks. (A) Representative hematoxylin and eosin-stained
images of lung sections from age-matched 12-week-old STING N153S mice and littermate
control mice. Upper panel images were taken under low magnification, lower panel images were
taken under high magnification. Scale bar = 100

m. (B) Quantitation of affected lung area of

STING N153S mice following administration of VNA or control. (C-E) 16S analysis on stool
samples collected from twelve-week-old, co-housed WT and STING N153S littermates. (F-L)
Gene expression of ISGs, cytokines, and chemokines following administration of VNA or
control. Data represent the mean +/- SEM of n = 5-13 mice per genotype pooled from 3
independent experiments. Results were analyzed by Mann-Whitney test. *, P < 0.05; ***, P <
0.001.
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Figure 3. VNA-treatment reduces pro-inflammatory cytokines, chemokines, and Th1
cytokine levels in the lungs of SAVI mice. Four-week-old STING N153S (SAVI) mice were
administered vancomycin, neomycin, and ampicillin cocktail (VNA) or vehicle control ad
libitum and euthanized at twelve weeks. Cytokine and chemokine levels were assessed by a
BioPlex assay of lung homogenates. Data represent the mean +/- SEM of n = 5-8 biological
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replicates group, which were pooled from 2 independent experiments. Results were analyzed by
Mann-Whitney test. *, P < 0.05; **, P < 0.01.
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Figure 4. Transplant of stool from VNA antibiotics-treated mice into germ-free SAVI mice
nearly eliminates STING-associated lung disease. Germ-free, co-housed WT and STING
N153S (SAVI) mice were either recolonized with stool from untreated STING N153S mice or
VNA-treated STING N153S mice. (A) Representative hematoxylin and eosin-stained images of
lung sections from age-matched 12- to 13-week-old STING N153S mice and littermate control
mice. Upper panel images were taken under low magnification, lower panel images were taken
under high magnification. Scale bar = 100

m. (B) Quantitation of affected lung area of STING

N153S mice with or without recolonization. (C-H) Gene expression of ISGs, cytokines, and
chemokines with or without recolonization. Data represent the mean +/- SEM of n = 8-16 mice
per group pooled from 2 independent experiments. Results were analyzed by Mann-Whitney test.
*, P < 0.05; **, P < 0.01.
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Figure 5. Metronidazole eliminates the lung-protective effects of other antibiotics. Tenweek-old STING N153S (SAVI) mice were administered vancomycin, neomycin, and ampicillin
cocktail (VNA) or vehicle control ad libitum and euthanized at twelve weeks. (A) Representative
hematoxylin and eosin-stained images of lung sections from age-matched 12-week-old STING
N153S mice. Upper panel images were taken under low magnification, lower panel images were
taken under high magnification. Scale bar = 100 µm. (B) Quantitation of affected lung area of
STING N153S mice following administration of VNA or control. Data represent the mean of n =
9-12 mice group, pooled from 3 independent experiments. Results were analyzed by MannWhitney test. **, P < 0.01; ***, P < 0.001.
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Figure 6. VNA-recolonized SAVI mice have a reduction in bacterial reads compared ESPF
and control recolonized mice, and an outgrowth of Bacteroidales not found in germ-free
samples. Ten-week-old STING N153S (SAVI) mice were recolonized with stool from VNAtreated STING N153S animals or left germ-free and stool was collected at twelve weeks. (A)
Bacterial family reads obtained from metagenomic sequencing of stool DNA from ESPF, control
recolonized, VNA-recolonized, or germ-free STING N153S mice. (B) Bacterial family relative
abundance obtained from metagenomic sequencing of stool DNA from ESPF, control
recolonized, VNA-recolonized, or germ-free STING N153S mice. (C) Bacterial species reads
obtained from metagenomic sequencing of stool DNA from VNA-recolonized, or germ-free
STING N153S mice. (D) Bacterial species relative abundance obtained from metagenomic
sequencing of stool DNA from VNA-recolonized, or germ-free STING N153S mice. Species
unique to VNA-recolonized samples are shown as bolded. Data represent samples collected from
n = 3 mice per condition pooled from 2 independent experiments.
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Figure 7. Recolonization with Bacteroides thetaiotaomicron, and treatment with propionate
and butyrate protect against STING-associated lung disease in mice. Ten-week-old, cohoused WT and STING N153S (SAVI) mice were either recolonized with B. theta or vehicle
control. (A). Representative hematoxylin and eosin-stained images of lung sections from agematched 12- to 13-week-old STING N153S mice and littermate control mice. Upper panel
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images were taken under low magnification, lower panel images were taken under high
magnification. Scale bar = 100 um. (B). Quantitation of affected lung area of STING N153S
mice with or without recolonization. (C-G) Gene expression of ISGs, cytokines, and chemokines
with or without recolonization. Data represent the mean +/- SEM of n = 5-6 mice per group
pooled from 2 independent experiments and were analyzed using Mann-Whitney test. Ten-weekold, Co-housed WT and STING N153S mice were given vehicle control, 1 mg/kg propionate, or
1 mg/kg butyrate daily for two weeks via intraperitoneal injection and were euthanized at twelve
weeks. (H) Representative hematoxylin and eosin-stained images of lung sections from agematched 12-week-old STING N153S mice and littermate control mice. Scale bar = 100 µm. (I).
Quantitation of affected lung area of STING N153S mice following administration of propionate
or vehicle control. Data in (H) and (I) represent the mean of n = 6-12 mice per group, pooled
from 2 independent experiments. Data were analyzed using Mann-Whitney test. *, P < 0.05; **,
P < 0.01.
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Figure S1. Lung disease recurs after stopping treatment of SAVI mice with the VNA
antibiotics cocktail. Related to Figure 2. Four-week-old STING N153S (SAVI) mice were
administered VNA or vehicle control ad libitum, switched to normal drinking water at eight
weeks, and euthanized at twelve weeks. (A) Representative hematoxylin and eosin-stained
images of lung sections from age-matched 12-week-old STING N153S mice and littermate
control mice. Upper panel images were taken under low magnification, lower panel images were
taken under high magnification. Scale bar = 100 µm. (B) Quantitation of affected lung area of
STING N153S mice following administration of VNA or control. Data represent the mean of n =
5-6 mice per group pooled from 2 independent experiments. Results were analyzed by MannWhitney test.
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Figure S2. Co-housed SAVI and WT littermate mice have similar gut microbial
compositions. Related to Figures 2 and 6. Twelve-week-old, co-housed WT and STING
N153S (SAVI) mice were administered VNA or vehicle control ad libitum and stool was
collected. 16S (A) and virome (B-E) analysis on stool samples collected from twelve-week-old,
co-housed WT and STING N153S littermates. Data represent the mean +/- SEM of samples
collected from n = 7-19 co-housed WT and STING N153S animals per genotype pooled from 3
independent timepoints. Results were analyzed by Mann-Whitney test.
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Figure S3. Treating mice with the VNA antibiotic cocktail alters T-cell populations in SAVI
animals. Related to Figures 2 and 3. Four-week-old STING N153S (SAVI) mice were
administered vancomycin, neomycin, and ampicillin cocktail (VNA) or vehicle control ad
libitum and euthanized at twelve weeks. (A) Representative FACS plots of WT (left panels) and
STING N153S (right panels) CD45+CD3+CD4+ cells. Cell frequencies within each gate are
denoted in red. (B-E) Percent and total number of naïve CD4+ T cells (CD44-CD62L+) and
effector CD4+ T cells (CD44+CD62L-). (F) Representative FACS plots of WT (left panels) and
STING N153S (right panels) CD45+CD3+CD8+ cells. Cell frequencies within each gate are
denoted in red. Percent and total number of naïve CD8+ T cells (CD44-CD62L+) and effector
CD8+ T cells (CD44+CD62L-). Data represent the mean +/- SEM of results from n = 5-8 mice
per group, and were pooled from 2 independent experiments. Results were analyzed by MannWhitney test. *, P < 0.05; **, P < 0.01.
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Figure S4. Treatment with the VNA antibiotics cocktail reduces myeloid populations in
SAVI but not WT littermate control animals. Related to Figures 2 and 3. Four-week-old
STING N153S (SAVI) mice were administered vancomycin, neomycin, and ampicillin cocktail
(VNA) or vehicle control ad libitum and euthanized at twelve weeks. Representative FACS plots
of WT (left panels) and STING N153S (right panels) (A) CD45+Ly6G+ and CD45+Ly6G- cells,
(B) CD45+CD11c+MHCII+ cells, and (C) CD45+CD11b+Ly6C+ cells. Cell frequencies within
each gate are denoted in red. (D-I) Percent and total number of CD11c+ dendritic cells
(CD11c+MHCII+), inflammatory monocytes (CD11b+Ly6Chi), and neutrophils (Ly6G+). Data
represent the mean +/- SEM of samples analyzed from n = 5-8 mice per group, which were
pooled from 2 independent experiments. Results were analyzed by Mann-Whitney test. *, P <
0.05; **, P < 0.01.
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Figure S5. Germ-free and recolonized conditions lead to similar effector T-cell and myeloid
populations in SAVI animals. Related to Figure 4. Ten-week-old STING N153S (SAVI) mice
were recolonized with stool from untreated STING N153S animals or left germ-free and
euthanized at twelve weeks. (A-D) Percent and total number of naïve CD4+ T cells (CD44CD62L+) and effector CD4+ T cells (CD44+CD62L-). (E-H) Percent and total number of naïve
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CD8+ T cells (CD44-CD62L+) and effector CD8+ T cells (CD44+CD62L-). (I-P) Percent and total
number of CD11c+ dendritic cells (CD11c+MHCII+), inflammatory monocytes (CD11b+Ly6Chi),
and neutrophils (Ly6G+). Data represent the mean +/- SEM of samples analyzed from n = 7-12
mice per group, which were pooled from 2 independent experiments. Results were analyzed by
Mann-Whitney test. *, P < 0.05; **, P < 0.01.
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Figure S6. Germ-free conditions and recolonization with stool from VNA antibioticstreated lead to similar effector T cell and myeloid populations in SAVI animals. Related to
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Figure 4. Ten-week-old STING N153S (SAVI) mice were recolonized with stool from VNAtreated STING N153S animals or left germ-free and euthanized at twelve weeks. (A-D) Percent
and total number of naïve CD4+ T cells (CD44-CD62L+) and effector CD4+ T cells
(CD44+CD62L-). (E-H) Percent and total number of naïve CD8+ T cells (CD44-CD62L+) and
effector CD8+ T cells (CD44+CD62L-). (I-P) Percent and total number of CD11c+ dendritic cells
(CD11c+MHCII+), inflammatory monocytes (CD11b+Ly6Chi), and neutrophils (Ly6G+). Data
represent the mean +/- SEM of n = 4-15 mice group pooled from 2 independent experiments.
Results were analyzed by Mann-Whitney test. *, P < 0.05; **, P < 0.01.
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Figure S7. Co-housed SAVI and WT littermate mice exhibit similar eukaryotic gut
microbial compositions. Related to Figures 4 and 6. Twelve-week-old, co-housed WT and
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STING N153S (SAVI) mice were administered VNA or vehicle control ad libitum and stool was
collected, followed by 18S sequencing and analysis. (A) Relative abundance of microbial
families in individual stool samples. (B-C) Weighted and unweighted PCoA analysis of stool
samples. (D) Heatmap demonstrating presence of microbial groups in individual samples. Data
represent samples pooled from of n = 10 mice per genotype per condition with stool taken at 3
independent timepoints.
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STAR Methods
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be
fulfilled by the Lead Contact, Jonathan J. Miner (miner@wustl.edu).
Materials availability
This study did not generate new unique reagents. Commercially available reagents are indicated
in the Key Resources Table.
Data and code availability
The accession numbers for the rDNA and metagenomic sequencing data reported in this paper
are European Nucleotide Archive: PRJEB42379
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice. All protocols for animal studies were approved by the Institutional Animal Care
and Use Committees at the Washington University School of Medicine (assurance no. A-338101). Mice were housed in specific-pathogen-free mouse facilities at the Washington University
School of Medicine. STING N153S mice (SAVI mice) were generated on a C57BL/6
background using CRISPR/Cas9 as previously described104. In all experiments using SAVI mice,
co-housed WT littermates were used as controls. Germ-free and recolonized mice were housed in
the gnotobiotic mouse facility at the Washington University School of Medicine. Confirmation
of a germ-free environment is done by bi-weekly wet mount observation, anaerobic and aerobic
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culture, fungal culture, and monthly 16S and transnetyx sequencing. For recolonization studies,
co-housed WT and SAVI mice in ESPF conditions were given the VNA cocktail or Kool-Aid in
drinking water for two weeks. At the end of two weeks, fecal pellets from VNA- or Kool-Aidtreated SAVI animals were collected, then pooled and homogenized anaerobically into a liquid
mixture. Germ-free WT and SAVI mice were recolonized by oral gavage with the anaerobic
mixtures or left germ-free for two weeks. At the two week timepoint, mice were sacrificed, and
stool, lungs, and spleen were collected for subsequent processing. For Bacteroides
thetaiotaomicron recolonization studies, WT and SAVI mice were given the VNAM cocktail in
drinking water for two weeks. After stopping treatment for one day, mice were given 1 x 108
CFU B. theta or vehicle control via oral gavage. Two days later, the mice were given a second
oral gavage of 1 x 108 CFU B. theta or vehicle control. Two weeks after recolonization, mice
were sacrificed and organs were collected for subsequent processing. Power analysis was
conducted for Institutional Animal Care and Use Committee-approved in vivo studies in order to
determine the number of animals needed per experimental group. At least two independent
experiments were conducted to replicate findings. No outliers were excluded from analyses.
Approximately equal numbers of both sexes were used. The age and number of animals used for
each experiment is listed in the figure legends.
BMDM studies. Bone marrow-derived macrophages (BMDMs) were generated from bone
marrow cells flushed from the femurs and tibias of age-matched SAVI mice, WT littermates, and
STING Goldenticket mice. Then 2.5 x 106 cells were incubated at 37°C in 10-cm cell culture
plates in complete medium containing Dulbecco’s modified Eagle medium (DMEM) (catalog no.
D6429; Sigma), 10% fetal bovine serum (FBS) (catalog no. SH30070-03; HyClone), 1%
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penicillin and streptomycin (catalog no. 15140; Gibco), 1% sodium pyruvate (catalog no. 11360;
Gibco), and 1% L-glutamate (catalog no. 35050; Gibco), supplemented with 40 ng/mL of
macrophage colony-stimulating factor (M-CSF) (catalog no. 300-25; PeproTech), for 6 days. At
day 7, 1 x 105 of BMDMs were seeded in 12-well plates, Bis-(3'-5')-cyclic dimeric guanosine
monophosphate (c-di-GMP) and c-di-GMP control (known as 5'-pGpG) were transfected as
indicated using TransIT®-LT1 Transfection Reagent according to the manufacturer’s
instructions. For ISG quantitation, BMDMs were transfected with c-di-GMP at 0, 10, 100, 200,
400, 600, 800, 1000, or 2000 ng/ml. IFIT1 and ISG15 mRNA levels were measured by qRTPCR 6 hours after transfection. Gene expression (fold change as compared to the control, 0
ng/ml) was calculated using ΔΔCt after normalizing to GAPDH. To measure MHCI, MHCII,
CD80, and CD86, BMDMs were transfected with 2 µg/ml c-di-GMP or 5’-pGpG for 24 hours.
Cells were stained with antibodies against MHCII, MHCI, CD80, and CD86 and measured by
flow cytometry. Cells from approximately equal numbers of both sexes were used.
METHOD DETAILS
Histologic staining analysis. Mice were perfused with 20 mL of PBS, then lung samples
were isolated from mice, fixed in 4% paraformaldehyde for 48 hours at room temperature, and
suspended in 70% ethanol before being embedded in paraffin. Tissue sections (thickness of 5
m) were stained with hematoxylin and eosin, followed by image acquisition using a Nikon
Eclipse E400 microscope and NIS Elements software. Using ImageJ software
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, lung lesions

were encircled by a blinded researcher, who quantitated the number of pixels within lung lesions
divided by the total number of pixels in the lung tissue, excluding large airway spaces. For colon
histology, the entire length of the colon was removed from mice and gently flushed with 5 mL of
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PBS, followed by 5 mL of 4% paraformaldehyde with blunt tipped needles. Next, scissors were
used to cut a straight line along the length of the colon. With epithelial layer facing up, colon
samples were pinned out and fixed in 4% paraformaldehyde for 16h at room temperature. The
fixed tissue was washed with 70% ethanol three times and then embedded in 2% agar, followed
by paraffin embedding, sectioning, and hematoxylin and eosin staining.
Flow cytometry. Spleens were crushed and filtered through a 70-um cell strainer to
generate single-cell suspensions. Cells were incubated with antibodies in PBS/4% FBS for 30
minutes, including fluorescently-conjugated antibodies specific for CD3, CD4, CD8a, CD11b,
CD11c, CD19, CD45, F4/80, Ly6C, Ly6G, MHCII, and NK1.1 (All antibodies from
BioLegend). Next, splenocytes were washed twice with PBS/4% FBS and analyzed on a BD
FACS Canto II or Thermo Fisher Scientific Attune NxT Flow Cytometer. Flow cytometry data
were analyzed with FlowJo software.
Multiplex cytokine assay. Lungs were harvested and homogenized in 200 µL of PBS.
Cytokine and chemokine levels were measured with the Bio-Plex Pro Mouse Cytokine Group I
Panel 23-Plex Assay Kit (Bio-Rad Laboratories, Hercules, California) on a Luminex platform.
Twenty-three cytokines and chemokines were examined.
16S rDNA sequencing and analysis. Fecal pellets were collected from co-housed WT
and SAVI mice and stored at -80ºC. DNA was extracted from fecal pellets using
phenol:chloroform and purified using the DNeasy Blood and Tissue Kit. (QIAGEN) per
manufacturer’s instructions. Primer selection and PCRs were performed as described previously
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. Samples were amplified in triplicate using Golay-barcoded primers specific to the V4 region

within the 16S rRNA gene. Amplified samples were then consolidated, and sample quality was
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determined using gel electrophoresis. Platinum High-Fidelity Taq (Invitrogen) was used to
amplify genomic DNA by PCR and amplicons were pooled and purified using 0.6x Agencourt
Ampure XP beads (Beckman-Coulter) according to the manufacturer’s instructions, and
quantitated using Qubit (ThermoFisher). The DNA pool was then sequenced using the Illumina
MiSeq platform. Sequencing data was analyzed using Quantitative Insights into Microbial
Ecology software (QIIME, version 1.8.0) 228.
18S sequencing and analysis. Fecal pellets were collected from co-housed WT and
SAVI mice following two-week administration of VNA or Kool-Aid in drinking water. Samples
were stored at -80ºC. DNA was extracted using the QIAamp Fast DNA Stool Mini Kit
(QIAGEN) and submitted to CD Genomics for 18S sequencing and data analysis.
Metagenomic sequencing and analysis. Fecal pellets were collected from germ-free
mice and mice recolonized with stool from VNA-treated SAVI mice. Fecal samples were stored
at -80ºC. DNA was extracted from fecal pellets using phenol:chloroform and purified using the
DNeasy Blood and Tissue Kit. (QIAGEN) per manufacturer’s instructions. Next, we performed
tagmentation on the samples, followed by purification using 0.6x Agencourt Ampure XP beads
(Beckman-Coulter) according to the manufacturer’s instructions. Samples were prepared for
shotgun sequencing using a modified version of a previously described protocol
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use of the Nextera DNA Library Prep Kit (Catalog # FC-121-1030/1031). Raw sequencing reads
were quality filtered and trimmed using BBTools v38.26. Samples then had any PhiX
contamination removed and were screened against the mouse reference genome to remove any
host reads. Paired-end reads were then interleaved into a single file for analysis. Samples were
then uploaded to the One Codex analysis platform and screened against the One Codex
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Database. Differences between samples were first examined at the Family level selecting any
taxa with >0.1% Relative Abundance. Germ-free and VNA Re-colonized mice were compared at
the Species level with the same cutoffs.
Gene expression analysis. Total RNA from lung homogenates or BMDMs was isolated
using the RNeasy kit (QIAGEN) per the manufacturer’s protocol. TaqMan RNA-to-Ct 1-step kit
(Applied Biosystems) was used to measure mRNA expression. Primer and probe assays were
obtained from Integrated DNA Technologies. DDCt values were calculated and then normalized
to the untreated WT samples. All samples analyzed were normalized to the house keeping gene
(GAPDH). Samples where the target gene did not amplify were assigned a CT value of 38 as the
limit of detection.
Short-chain fatty acid treatment. Propionate and butyrate solutions were prepared in
sterile PBS. Co-housed, WT and SAVI mice were given either PBS, propionate, or butyrate at a
concentration of 1 mg/kg body weight and volume of 200 µL via intraperitoneal injection. Mice
were injected daily for 14 days and euthanized on day 14. Lungs were fixed and submitted for
H&E staining.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data were analyzed using GraphPad Prism software by Mann-Whitney test as specified in the
figure legends.
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Conclusion
The immune system must provide an immunological landscape by which the human body
can be protected against pathogenic insult while avoiding self-damage. In order to accomplish
this feat, the immune system must carefully regulate itself such that it becomes activated in order
to combat invading pathogens and related antigens, but remains tolerogenic in the presence of
self-antigens. Autoinflammation and autoimmunity occur when the host immune system is
unable to properly inactivate the immunological repertoire in response to self. Interestingly,
many of the same immune pathways and molecules that provide protection against pathogenic
threats are thought to be responsible for immunopathology that is observed in autoinflammatory
and autoimmune disease. For this thesis work, we sought to investigate immune pathways that
exist at the intersection of immune responses to pathogens and immune responses to self, as well
as assess the resulting immunopathology. In particular, we focused on interferon signaling and
cytosolic nucleic acid sensing pathways, both of which are necessary for robust immune
responses to pathogenic microbes.
The ability of ZIKV to cause transplacental infection and congenital malformations
became apparent during the explosive 2015-2016 ZIKV epidemic in Central and South America.
However, the ability of other flaviviruses to infect the placenta and developing fetus and cause
fetal

demise

and

long-term

neurological

sequelae

in

surviving

fetuses

remained

underappreciated. In the second chapter of this thesis, we compared numerous neurotropic
flaviviruses and arthritogenic alphaviruses and evaluated their capacity to replicate in the mouse
placenta, the developing mouse fetus, and human placental explants. Our findings demonstrated
that WNV and POWV, both highly virulent neurotropic flaviviruses, are able to cross the
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placenta cause damage to the developing fetus. In contrast, the tested alphaviruses, CHIKV and
MAYV, were unable to cross the placenta and cause congenital disease in mice, and replicated
very poorly in human placental explants. Furthermore, we observed elevated ISG levels in the
flavivirus-infected mouse placental and fetal head samples, but not the alphavirus-infected
samples. Interestingly, subsequent studies by a different laboratory demonstrated that type I IFN
responses at the maternal-fetal interface exacerbate placental and fetal infection and resulting
immunopathology55. Whether differences in the type I IFN response contributed to the more
severe congenital phenotypes following flavivirus infection was not assessed, but remains a
possibility.
Unlike type I IFN signaling, which may be deleterious at the maternal-fetal interface,
type III IFN signaling in placental cell such as trophoblasts is protective against viral infection.
IFN-l signaling, which controls infections more locally at barrier surfaces, also promotes
antiviral activity against both DNA and RNA viruses in the cornea. Indeed, we demonstrated that
IFN-l eye drops induce IFNlR-dependent ISG upregulation, and pretreatment with IFNlR1blocking antibodies increases the susceptibility of human corneal explants to HSV-1 and ZIKV
infection. In contrast, SARS-CoV-2 could not replicate or persist in the human cornea even with
IFNlR1 blockade (Fig. 1). Although IFN-l is protective against HSV-1 and ZIKV infection in
the cornea, the mechanism by which IFN-l becomes activated was not established. One known
up-stream activator of IFN-l signaling is RIG-I, an RNA-sensing PRR that signals through
mitochondrial antiviral signaling protein (MAVS)230. While this may contribute to IFN-l
activation in response to ZIKV infection, it is less likely that it has an important function in
response to a DNA virus such as HSV-1. Another pathway that may be involved in IFN-l
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production is the cGAS-STING signaling pathway. Although STING is mainly associated with
the type I IFN response, studies in HEK293T cells have demonstrated STING-dependent IFN-l1
production in response to HSV-2 infection231. Furthermore, STING is known to activate IFN
signaling in response to both DNA and RNA viruses70,71. Thus, cGAS-STING signaling may be
key to the IFN-l response in the cornea. Since genetic ablation of STING in human corneal
explants is likely not possible, we would need to address this question using RNA interference to
knockdown STING expression in primary human corneal epithelial cells or, alternatively,
knockout STING using CRISPR-Cas9 in an immortalized human corneal epithelial cell line.
Genetic ablation of STING, followed by subsequent viral challenge and measurement of IFN-l
expression, will allow us to determine whether IFN-l signaling in the cornea is STING-mediated
or occurs via a different mechanism.
The cGAS-STING signaling pathway is an important regulator of type I IFN and ISG
production and thus plays an important role in controlling flavivirus infection. Our laboratory
and others previously demonstrating that the loss of STING leads to increased lethality in
response to infection by flaviviruses such as WNV85,232. Interestingly, gain-of-function mutations
in STING also lead to severe autoimmunity and immunodeficiency in mice
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, demonstrating

the importance of properly regulated STING signaling. Although the importance of STING in
controlling viral infections and the ability of STING gain-of-function to cause autoimmune
disease were both known, the involvement of microbes in the development of STING-associated
autoinflammation and autoimmunity had not previously been defined. By performing studies at
this intersection, this thesis sought to provide insight into the ways in which commensal
microbes influence autoinflammation and autoimmune disease.
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Using our mouse model of SAVI, we discovered that treatment with an antibiotic cocktail
(VNA) nearly eliminates autoinflammatory lung disease in SAVI mice. Furthermore, this
reduction in perivascular inflammation was accompanied by a decrease in pro-inflammatory
cytokines and chemokines in the lungs. VNA antibiotics treatment also corrected issues in
immune cell compartments of SAVI mice such as myeloid and effector T cell expansion, and
diminished naïve T cell numbers. This finding, in addition to our data demonstrating that the
STING N153S mutant renders STING hyper-responsive to c-di-GMP, suggested to us that the
presence of bacteria was a primary driver of lung disease in SAVI mice. To our surprise, germfree SAVI mice still developed lung disease. By performing metagenomic sequencing on germfree SAVI mice that were recolonized with stool from VNA antibiotics-treated mice, we
identified Bacteroidales as an order of bacteria that was potentially protective (Fig. 2).
Recolonization with B. theta confirmed our hypothesis that Bacteroidales species bacteria
can be protective, but we were not able to determine the immunological mechanism by which
protection occurs. One possibility we considered was that short-chain fatty acids, which have
well studied immunomodulatory properties209,210, might be responsible for the Bacteroidalesmediated amelioration of perivascular inflammation in the lungs of recolonized SAVI mice.
Interestingly, treatment with short-chain fatty acids propionate and butyrate was able to
reproduce the protective effect. Although we were able to provide sufficient evidence to propose
a potential mechanism by which enrichment with Bacteroidales protects against lung disease in
SAVI mice, multiple questions remain unanswered. (1) Are Bacteroidales-produced short-chain
fatty acids the key metabolite required for reduction in lung disease? (2) If so, what is the precise
mechanism by which short-chain fatty acids reduce lung disease? (3) If not, what is the key
metabolite required for protection against perivascular lung inflammation?
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We have considered numerous additional studies that may aid in answering these
questions. Recolonization of germ-free or antibiotics-treated SAVI mice with a Bacteroidalesspecies strain (such as B. theta) that is unable to produce short-chain fatty acids would be able to
address this question. Since a B. theta strain that does not produce propionate has been
generated, we can use this strain to test the hypothesis that short-chain fatty acids are the key
protective metabolite produced by Bacteroidales. If short-chain fatty acid-deficient B. theta are
unable to protect against the development of autoinflammatory lung disease in SAVI mice, we
will have more direct evidence in favor of the requirement of short-chain fatty acid production
for protection. Since T cells are primary drivers of perivascular inflammation in the lung, one
potential mechanism by which short-chain fatty acids could reduce lung disease is through direct
effects on T cells. While we did not observe significant changes in T cell numbers in recolonized
mice, short-chain fatty acids can modulate cellular metabolism, memory potential, metabolicepigenetic crosstalk, and differentiation of T cells233-235. Through one of these mechanisms,
short-chain fatty acids might modulate T cell function in SAVI mice, thus reducing
autoinflammatory lung disease. Alternatively, short-chain fatty acids may be exerting their
immunomodulatory effects on other cell types.
While we have demonstrated that short-chain fatty acids have the capacity to reduce lung
disease in SAVI mice, we cannot exclude the possibility other microbial metabolites are key to
protection in recolonized mice. Secondary bile acids are common metabolites derived
predominantly by intestinal bacteria, including those from the Bacteroides genus236. Numerous
studies have identified immunomodulatory properties of secondary bile acids237-239. The
possibility remains that alteration of the gut microbiota could lead to the increased production of
secondary bile acids that have anti-inflammatory activity in SAVI mice. Bile acids signal
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through a group of G-protein coupled receptors and nuclear receptors that are collectively
referred to as bile acid receptors (BARs) and can be either activated or inhibited by bile acids236.
Two such BARs, G-protein bile acid receptor 1 (GPBAR1) and Farnesoid-X-Receptor (FXR) are
expressed in not only intestinal epithelial cells, but also immune cells such as monocytes and
macrophages, dendritic cells, NK cells, and T and B cells236,240-243 . Small molecule agonists that
target GPBAR1 have been shown to ameliorate disease in an experimental autoimmune
encephalitis model244, so the capacity of secondary bile acids to modulate autoimmune disease in
SAVI mice remains an intriguing possibility.
Although we demonstrated that relative enrichment of Bacteroidales and recolonization
with B. theta can protect against autoinflammatory lung disease, we were unable to identify a
protective molecule. Short-chain fatty acids and secondary bile acids are prime candidates due to
their abundance in the intestine and known immunomodulatory properties, but definitively
identifying and isolating the protective factor will require a systematic approach. Since the factor
is present in stool from VNA-treated animals, the approach will begin with fecal samples.
Combined with our finding that Bacteroides can protect against lung disease and remains present
in the gut after VNA-treatment, a focused metabolomics-based approach will allow us to
consider all likely candidates. We will first filter pooled fecal samples from VNA-treated SAVI
mice and divide it into cellular material and acellular material. Next, we will use UV light to
inactivate potential viruses in the acellular material, leaving us with non-infectious molecules. In
collaboration with the Biomedical Mass Spectrometry Core, we will be able to identify key
molecules, highlighting those associated with bacteria of the order Bacteroidales. By treating
germ-free SAVI mice with these molecules either individually or in combination, we may be
able to identify the factors responsible for protection against perivascular lung inflammation in
123

SAVI mice. Another method would require culturing of bacteria from germ-free SAVI mice that
have been recolonized with stool from VNA-treated SAVI animals. We were unsuccessful in our
attempts to culture bacteria directly from fecal samples obtained from VNA-treated mice, but
microbial expansion in recolonized SAVI mice may improve our odds.
Our experiments were performed using WT and SAVI littermates, yet we observed a
range within the severity of lung disease in SAVI mice. Because bacteria modulate
autoinflammatory lung disease in SAVI mice, there exists the possibility that the severity of lung
disease is influenced by cage effects. By using separately-housed mice, we can assess the
potential contributions of cage effects on autoinflammatory disease variance. Furthermore, we
may highlight differences that would have been less clear in previous datasets due to pooling of
fecal samples for 16S and metagenomic analysis. Moreover, our creation of germ-free SAVI
mice will allow us to ask and answer numerous questions that would be more difficult to address
using conventionally-housed mice. For example, recolonization of germ-free SAVI mice with
samples from SAVI patients and controls, followed by 16S analysis, may allow us to obtain new
insights into the effects of the human microbiota on autoimmune disease. With this model, our
laboratory is uniquely positioned to perform reverse translational research that will enable us to
investigate ways to alter the microbiota from SAVI patients and study its effects on systemic
autoimmunity. These findings may pave the way for novel, microbiota-based ways to
therapeutically treat SAVI patients. Alternatively, a greater mechanistic understanding of the
pathway(s) involved in bacterial modulation of autoinflammatory disease in SAVI mice could
provide insight into druggable targets for SAVI patients in the future.
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This thesis work sought to provide novel insight into the ways in which cytosolic nucleic
acid sensing and interferon signaling regulate host-microbe interactions within the context of
autoimmunity, immune responses to viral infections, and related immunopathology. Our findings
have built upon the fields of antiviral immunity and autoimmune disease, and may pave the way
for therapeutics that can be used to combat viral infection and autoimmunity.
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Figure 1. IFN-l signaling and antiviral growth restriction in the human cornea. Exogenous
IFN-l up-regulates antiviral ISG expression in the human cornea. Blockade of IFNlR1 renders
human corneal explants more permissive to infection by HSV-1 and ZIKV. In contrast, SARSCoV-2 is unable to replicate in human corneal explants even following IFNlR1 inhibition245.
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Figure 2. Bacteroidales enrichment reduces autoinflammatory lung disease in SAVI mice.
Conventionally-housed and germ-free STING N153S (SAVI) mice develop severe perivascular
inflammation. Relative enrichment of Bacteroidales bacteria by oral antibiotics in
conventionally-housed SAVI mice, or by recolonization with a Bacteroidales-enriched fecal
transplant in germ-free SAVI mice, restricts the development of autoinflammatory lung
disease246.
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